JP4988604B2 - グルカゴン受容体アンタゴニストとしての置換チオフェン誘導体、その調製及び治療への使用 - Google Patents
グルカゴン受容体アンタゴニストとしての置換チオフェン誘導体、その調製及び治療への使用 Download PDFInfo
- Publication number
- JP4988604B2 JP4988604B2 JP2007555195A JP2007555195A JP4988604B2 JP 4988604 B2 JP4988604 B2 JP 4988604B2 JP 2007555195 A JP2007555195 A JP 2007555195A JP 2007555195 A JP2007555195 A JP 2007555195A JP 4988604 B2 JP4988604 B2 JP 4988604B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- biphenyl
- dimethyl
- cycloalkyl
- nitrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940122904 Glucagon receptor antagonist Drugs 0.000 title abstract description 5
- 238000002360 preparation method Methods 0.000 title description 198
- 230000001225 therapeutic effect Effects 0.000 title description 4
- 150000003577 thiophenes Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 426
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 134
- 150000003839 salts Chemical class 0.000 claims abstract description 66
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 213
- -1 - nitro Chemical group 0.000 claims description 112
- 229910052739 hydrogen Inorganic materials 0.000 claims description 107
- 239000001257 hydrogen Substances 0.000 claims description 106
- 229910052736 halogen Inorganic materials 0.000 claims description 98
- 150000002367 halogens Chemical class 0.000 claims description 64
- 125000003545 alkoxy group Chemical group 0.000 claims description 63
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 47
- 229910052799 carbon Inorganic materials 0.000 claims description 42
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 39
- 125000003342 alkenyl group Chemical group 0.000 claims description 31
- 125000001424 substituent group Chemical group 0.000 claims description 31
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 28
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 28
- 125000001475 halogen functional group Chemical group 0.000 claims description 27
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 22
- 125000004429 atom Chemical group 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 306
- 229960004666 glucagon Drugs 0.000 abstract description 69
- 102000051325 Glucagon Human genes 0.000 abstract description 63
- 108060003199 Glucagon Proteins 0.000 abstract description 63
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract description 63
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 27
- 230000000694 effects Effects 0.000 abstract description 19
- 208000030159 metabolic disease Diseases 0.000 abstract description 10
- 239000000543 intermediate Substances 0.000 abstract description 8
- 229940125425 inverse agonist Drugs 0.000 abstract description 4
- 239000002469 receptor inverse agonist Substances 0.000 abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 307
- 239000007858 starting material Substances 0.000 description 193
- 235000019439 ethyl acetate Nutrition 0.000 description 113
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 107
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 92
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 89
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 81
- 239000002253 acid Substances 0.000 description 81
- 239000000203 mixture Substances 0.000 description 73
- 230000008569 process Effects 0.000 description 70
- 239000011541 reaction mixture Substances 0.000 description 70
- 239000000243 solution Substances 0.000 description 69
- 238000006243 chemical reaction Methods 0.000 description 67
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 63
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 49
- 108010063919 Glucagon Receptors Proteins 0.000 description 48
- 102100040890 Glucagon receptor Human genes 0.000 description 48
- 150000004702 methyl esters Chemical class 0.000 description 47
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 46
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 45
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 45
- 239000000741 silica gel Substances 0.000 description 44
- 229910002027 silica gel Inorganic materials 0.000 description 44
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 42
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 35
- 239000012044 organic layer Substances 0.000 description 34
- 239000010410 layer Substances 0.000 description 32
- 238000011282 treatment Methods 0.000 description 32
- 150000002148 esters Chemical class 0.000 description 28
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 27
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 27
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 26
- 239000003480 eluent Substances 0.000 description 26
- 239000000463 material Substances 0.000 description 26
- 238000004296 chiral HPLC Methods 0.000 description 25
- 238000002835 absorbance Methods 0.000 description 24
- 239000012267 brine Substances 0.000 description 24
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 24
- 239000000284 extract Substances 0.000 description 22
- 239000000556 agonist Substances 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- XPGRZDJXVKFLHQ-UHFFFAOYSA-N hydron;methyl 3-aminopropanoate;chloride Chemical compound Cl.COC(=O)CCN XPGRZDJXVKFLHQ-UHFFFAOYSA-N 0.000 description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 20
- 239000006260 foam Substances 0.000 description 19
- 108090001061 Insulin Proteins 0.000 description 18
- 102000004877 Insulin Human genes 0.000 description 18
- 239000005557 antagonist Substances 0.000 description 18
- 125000004432 carbon atom Chemical group C* 0.000 description 18
- 229940125396 insulin Drugs 0.000 description 18
- 238000000926 separation method Methods 0.000 description 18
- 239000003814 drug Substances 0.000 description 17
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 17
- 238000010992 reflux Methods 0.000 description 17
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 16
- 241000124008 Mammalia Species 0.000 description 16
- 125000003118 aryl group Chemical group 0.000 description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 16
- 239000007787 solid Substances 0.000 description 16
- 239000000047 product Substances 0.000 description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- 239000002585 base Substances 0.000 description 14
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 14
- 230000027455 binding Effects 0.000 description 14
- 229940017219 methyl propionate Drugs 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- UAHZCJDIUCCRHT-UHFFFAOYSA-N 3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenol Chemical compound CC1=CC(O)=CC(C)=C1C1=CC=C(C(F)(F)F)C=C1 UAHZCJDIUCCRHT-UHFFFAOYSA-N 0.000 description 13
- RIYABMKGORLKGD-UHFFFAOYSA-N 4-(4-tert-butylphenyl)-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1C1=CC=C(C(C)(C)C)C=C1 RIYABMKGORLKGD-UHFFFAOYSA-N 0.000 description 13
- 239000008103 glucose Substances 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 13
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 238000007429 general method Methods 0.000 description 12
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 12
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 12
- AFPOYLCQXONCPX-UHFFFAOYSA-N 4-[4-(trifluoromethyl)phenyl]phenol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C(F)(F)F)C=C1 AFPOYLCQXONCPX-UHFFFAOYSA-N 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 238000001816 cooling Methods 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 201000001421 hyperglycemia Diseases 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- 239000006188 syrup Substances 0.000 description 11
- 235000020357 syrup Nutrition 0.000 description 11
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 10
- 208000008589 Obesity Diseases 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 10
- KFPZQIYCDXHRED-UHFFFAOYSA-N ethyl 5-formylthiophene-2-carboxylate Chemical compound CCOC(=O)C1=CC=C(C=O)S1 KFPZQIYCDXHRED-UHFFFAOYSA-N 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- 235000020824 obesity Nutrition 0.000 description 10
- 235000019260 propionic acid Nutrition 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- UAYWVJHJZHQCIE-UHFFFAOYSA-L zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 description 10
- JUMBSPQABSHVMN-UHFFFAOYSA-N (4-tert-butylphenoxy)boronic acid Chemical compound CC(C)(C)C1=CC=C(OB(O)O)C=C1 JUMBSPQABSHVMN-UHFFFAOYSA-N 0.000 description 9
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 239000000883 anti-obesity agent Substances 0.000 description 9
- 229940125710 antiobesity agent Drugs 0.000 description 9
- 239000011324 bead Substances 0.000 description 9
- 239000000460 chlorine Chemical group 0.000 description 9
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 239000012299 nitrogen atmosphere Substances 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 9
- 0 C*c1ccc[n]1 Chemical compound C*c1ccc[n]1 0.000 description 8
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 8
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 8
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 8
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 8
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 8
- 239000011698 potassium fluoride Substances 0.000 description 8
- 235000003270 potassium fluoride Nutrition 0.000 description 8
- 238000000159 protein binding assay Methods 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 8
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 description 7
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 7
- XITRDELMZYWONF-UHFFFAOYSA-N 4-(4-tert-butylphenyl)-3-methylphenol Chemical compound CC1=CC(O)=CC=C1C1=CC=C(C(C)(C)C)C=C1 XITRDELMZYWONF-UHFFFAOYSA-N 0.000 description 7
- 102100040918 Pro-glucagon Human genes 0.000 description 7
- 229940100389 Sulfonylurea Drugs 0.000 description 7
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 7
- 230000036755 cellular response Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 238000003818 flash chromatography Methods 0.000 description 7
- 150000002431 hydrogen Chemical group 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 229960003105 metformin Drugs 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 7
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- JEBLXYMEFUOKFB-UHFFFAOYSA-N 3-[[5-[1-[4-(4-tert-butylphenyl)-3,5-dimethylphenyl]sulfanylethyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)SC=1C(C)SC(C=C1C)=CC(C)=C1C1=CC=C(C(C)(C)C)C=C1 JEBLXYMEFUOKFB-UHFFFAOYSA-N 0.000 description 6
- ZNWRRSQYWUYNEI-UHFFFAOYSA-N 3-methyl-4-[4-(trifluoromethyl)phenyl]phenol Chemical compound CC1=CC(O)=CC=C1C1=CC=C(C(F)(F)F)C=C1 ZNWRRSQYWUYNEI-UHFFFAOYSA-N 0.000 description 6
- RMJZLNUEDDXELD-UHFFFAOYSA-N 4-iodo-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1I RMJZLNUEDDXELD-UHFFFAOYSA-N 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- 201000001320 Atherosclerosis Diseases 0.000 description 6
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 6
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 6
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 6
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 102000034527 Retinoid X Receptors Human genes 0.000 description 6
- 108010038912 Retinoid X Receptors Proteins 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- HCIMXTXCDVBLOA-UHFFFAOYSA-N [4-(trifluoromethyl)phenoxy]boronic acid Chemical compound OB(O)OC1=CC=C(C(F)(F)F)C=C1 HCIMXTXCDVBLOA-UHFFFAOYSA-N 0.000 description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 6
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 6
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 6
- OQJBFFCUFALWQL-UHFFFAOYSA-N n-(piperidine-1-carbonylimino)piperidine-1-carboxamide Chemical compound C1CCCCN1C(=O)N=NC(=O)N1CCCCC1 OQJBFFCUFALWQL-UHFFFAOYSA-N 0.000 description 6
- 230000007823 neuropathy Effects 0.000 description 6
- 125000006574 non-aromatic ring group Chemical group 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- WCWWQRBHBLQNOJ-UHFFFAOYSA-N 3-[[5-[1-[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenyl]sulfanylbutyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)SC=1C(CCC)SC(C=C1C)=CC(C)=C1C1=CC=C(C(F)(F)F)C=C1 WCWWQRBHBLQNOJ-UHFFFAOYSA-N 0.000 description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 5
- RYXZOQOZERSHHQ-UHFFFAOYSA-N [2-(2-diphenylphosphanylphenoxy)phenyl]-diphenylphosphane Chemical compound C=1C=CC=C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)C=1OC1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RYXZOQOZERSHHQ-UHFFFAOYSA-N 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 239000012062 aqueous buffer Substances 0.000 description 5
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 5
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 5
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 5
- ZXSBDSGRQIWJPM-UHFFFAOYSA-N dimethylcarbamothioic s-acid Chemical compound CN(C)C(S)=O ZXSBDSGRQIWJPM-UHFFFAOYSA-N 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- JZGZKRJVTIRPOK-UHFFFAOYSA-N ethyl thiophene-2-carboxylate Chemical compound CCOC(=O)C1=CC=CS1 JZGZKRJVTIRPOK-UHFFFAOYSA-N 0.000 description 5
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 5
- 244000144972 livestock Species 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 150000007522 mineralic acids Chemical class 0.000 description 5
- 208000031225 myocardial ischemia Diseases 0.000 description 5
- DAZXVJBJRMWXJP-UHFFFAOYSA-N n,n-dimethylethylamine Chemical compound CCN(C)C DAZXVJBJRMWXJP-UHFFFAOYSA-N 0.000 description 5
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- CKAKJLZACKBKCK-CGHJUBPDSA-N (2r)-3-[[5-[1-[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenoxy]-2-methylpropyl]thiophene-2-carbonyl]amino]-2-hydroxypropanoic acid Chemical compound C=1C=C(C(=O)NC[C@@H](O)C(O)=O)SC=1C(C(C)C)OC(C=C1C)=CC(C)=C1C1=CC=C(C(F)(F)F)C=C1 CKAKJLZACKBKCK-CGHJUBPDSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- AGUPDECMODEFMA-UHFFFAOYSA-N 3-[[5-[1-[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenoxy]propyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)SC=1C(CC)OC(C=C1C)=CC(C)=C1C1=CC=C(C(F)(F)F)C=C1 AGUPDECMODEFMA-UHFFFAOYSA-N 0.000 description 4
- INKDBZXBBCUQMR-UHFFFAOYSA-N 3-[[5-[3,3-dimethyl-1-[3-methyl-4-[4-(trifluoromethyl)phenyl]phenoxy]butyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C=C(C=2C=CC(=CC=2)C(F)(F)F)C(C)=CC=1OC(CC(C)(C)C)C1=CC=C(C(=O)NCCC(O)=O)S1 INKDBZXBBCUQMR-UHFFFAOYSA-N 0.000 description 4
- YGHRJJRRZDOVPD-UHFFFAOYSA-N 3-methylbutanal Chemical compound CC(C)CC=O YGHRJJRRZDOVPD-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- SXZZNILOVVYVRN-UHFFFAOYSA-N 4-bromo-3,5-dimethylbenzenethiol Chemical compound CC1=CC(S)=CC(C)=C1Br SXZZNILOVVYVRN-UHFFFAOYSA-N 0.000 description 4
- 102000054930 Agouti-Related Human genes 0.000 description 4
- 101710127426 Agouti-related protein Proteins 0.000 description 4
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 4
- 208000033463 Ischaemic neuropathy Diseases 0.000 description 4
- 208000032382 Ischaemic stroke Diseases 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 4
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000003472 antidiabetic agent Substances 0.000 description 4
- 239000012148 binding buffer Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 125000002837 carbocyclic group Chemical group 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229960004580 glibenclamide Drugs 0.000 description 4
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- IMOYLHUPJKATBN-UHFFFAOYSA-N methyl 3-[[5-[1-(4-iodo-3,5-dimethylphenoxy)propyl]thiophene-2-carbonyl]amino]propanoate Chemical compound C=1C=C(C(=O)NCCC(=O)OC)SC=1C(CC)OC1=CC(C)=C(I)C(C)=C1 IMOYLHUPJKATBN-UHFFFAOYSA-N 0.000 description 4
- GNKNIDUKIKWLFM-UHFFFAOYSA-N methyl 3-[[5-[1-[4-[4-(trifluoromethyl)phenyl]phenoxy]ethyl]thiophene-2-carbonyl]amino]propanoate Chemical compound S1C(C(=O)NCCC(=O)OC)=CC=C1C(C)OC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 GNKNIDUKIKWLFM-UHFFFAOYSA-N 0.000 description 4
- PYYLMDRFZONATG-UHFFFAOYSA-N methyl 3-[[5-[3,3-dimethyl-1-[3-methyl-4-[4-(trifluoromethyl)phenyl]phenoxy]butyl]thiophene-2-carbonyl]amino]propanoate Chemical compound S1C(C(=O)NCCC(=O)OC)=CC=C1C(CC(C)(C)C)OC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C(C)=C1 PYYLMDRFZONATG-UHFFFAOYSA-N 0.000 description 4
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 4
- 229960000698 nateglinide Drugs 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229920000728 polyester Polymers 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 4
- 239000011975 tartaric acid Substances 0.000 description 4
- 235000002906 tartaric acid Nutrition 0.000 description 4
- BGHCVCJVXZWKCC-UHFFFAOYSA-N tetradecane Chemical compound CCCCCCCCCCCCCC BGHCVCJVXZWKCC-UHFFFAOYSA-N 0.000 description 4
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 3
- CCQCRVHVJHAXJB-UHFFFAOYSA-N (4-propan-2-ylphenoxy)boronic acid Chemical compound CC(C)C1=CC=C(OB(O)O)C=C1 CCQCRVHVJHAXJB-UHFFFAOYSA-N 0.000 description 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- OEJKFQIUGCSMPY-UHFFFAOYSA-N 3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]benzenethiol Chemical compound CC1=CC(S)=CC(C)=C1C1=CC=C(C(F)(F)F)C=C1 OEJKFQIUGCSMPY-UHFFFAOYSA-N 0.000 description 3
- ZOIZUVVGWNGIIT-UHFFFAOYSA-N 3-[[5-[1-[3,5-dimethyl-4-(4-propan-2-ylphenyl)phenyl]sulfanyl-2-methylpropyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)SC=1C(C(C)C)SC(C=C1C)=CC(C)=C1C1=CC=C(C(C)C)C=C1 ZOIZUVVGWNGIIT-UHFFFAOYSA-N 0.000 description 3
- QQQAOABVNLQAGW-UHFFFAOYSA-N 3-[[5-[1-[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenoxy]-3-methylbutyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)SC=1C(CC(C)C)OC(C=C1C)=CC(C)=C1C1=CC=C(C(F)(F)F)C=C1 QQQAOABVNLQAGW-UHFFFAOYSA-N 0.000 description 3
- AOJSIEGRVLSVRH-UHFFFAOYSA-N 3-[[5-[1-[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenyl]sulfanyl-2,2-dimethylpropyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C(C)=C(C=2C=CC(=CC=2)C(F)(F)F)C(C)=CC=1SC(C(C)(C)C)C1=CC=C(C(=O)NCCC(O)=O)S1 AOJSIEGRVLSVRH-UHFFFAOYSA-N 0.000 description 3
- DCFGJUDIBOPGGP-UHFFFAOYSA-N 3-[[5-[1-[4-(4-tert-butylphenyl)-3,5-dimethylphenoxy]ethyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)SC=1C(C)OC(C=C1C)=CC(C)=C1C1=CC=C(C(C)(C)C)C=C1 DCFGJUDIBOPGGP-UHFFFAOYSA-N 0.000 description 3
- NYLOFHQDPGBBKM-UHFFFAOYSA-N 3-[[5-[1-[4-(4-tert-butylphenyl)-3,5-dimethylphenoxy]propyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)SC=1C(CC)OC(C=C1C)=CC(C)=C1C1=CC=C(C(C)(C)C)C=C1 NYLOFHQDPGBBKM-UHFFFAOYSA-N 0.000 description 3
- ZXVUCBAQFNPLFI-UHFFFAOYSA-N 3-[[5-[1-[4-(4-tert-butylphenyl)-3,5-dimethylphenyl]sulfanyl-3-methylbutyl]thiophene-2-carbonyl]amino]propanoic acid Chemical class C=1C=C(C(=O)NCCC(O)=O)SC=1C(CC(C)C)SC(C=C1C)=CC(C)=C1C1=CC=C(C(C)(C)C)C=C1 ZXVUCBAQFNPLFI-UHFFFAOYSA-N 0.000 description 3
- FCAGKQUBXKXQCE-UHFFFAOYSA-N 3-[[5-[1-[4-(4-tert-butylphenyl)-3,5-dimethylphenyl]sulfanyl-4,4,4-trifluorobutyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C(C)=C(C=2C=CC(=CC=2)C(C)(C)C)C(C)=CC=1SC(CCC(F)(F)F)C1=CC=C(C(=O)NCCC(O)=O)S1 FCAGKQUBXKXQCE-UHFFFAOYSA-N 0.000 description 3
- IIIOUSCNDCVMFU-UHFFFAOYSA-N 3-[[5-[1-[4-[4-(trifluoromethyl)phenyl]phenoxy]ethyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)SC=1C(C)OC(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 IIIOUSCNDCVMFU-UHFFFAOYSA-N 0.000 description 3
- JTRCLMLKLIYUSF-UHFFFAOYSA-N 3-[[5-[1-[4-[4-(trifluoromethyl)phenyl]phenoxy]octyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)SC=1C(CCCCCCC)OC(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 JTRCLMLKLIYUSF-UHFFFAOYSA-N 0.000 description 3
- UGLRXZKFOQBOAC-UHFFFAOYSA-N 3-[[5-[2,2-dimethyl-1-[3-methyl-4-[4-(trifluoromethyl)phenyl]phenoxy]propyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C=C(C=2C=CC(=CC=2)C(F)(F)F)C(C)=CC=1OC(C(C)(C)C)C1=CC=C(C(=O)NCCC(O)=O)S1 UGLRXZKFOQBOAC-UHFFFAOYSA-N 0.000 description 3
- JDBAYLWBVQVMTD-UHFFFAOYSA-N 4,5-dichlorothiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC(Cl)=C(Cl)S1 JDBAYLWBVQVMTD-UHFFFAOYSA-N 0.000 description 3
- ZDXCAHXCFOZWBK-UHFFFAOYSA-N 4-(4-tert-butylphenyl)-3,5-dimethylbenzenethiol Chemical compound CC1=CC(S)=CC(C)=C1C1=CC=C(C(C)(C)C)C=C1 ZDXCAHXCFOZWBK-UHFFFAOYSA-N 0.000 description 3
- RAEVCPWJHSDYKQ-UHFFFAOYSA-N 4-chloro-5-(1-hydroxypropyl)thiophene-2-carboxylic acid Chemical compound CCC(O)C=1SC(C(O)=O)=CC=1Cl RAEVCPWJHSDYKQ-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- FNPDGXJJNCPDCS-UHFFFAOYSA-M CC(C)(C)CC[Mg]Br Chemical compound CC(C)(C)CC[Mg]Br FNPDGXJJNCPDCS-UHFFFAOYSA-M 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 102100021752 Corticoliberin Human genes 0.000 description 3
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 3
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 3
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 3
- 101001040075 Homo sapiens Glucagon receptor Proteins 0.000 description 3
- 101001015516 Homo sapiens Glucagon-like peptide 1 receptor Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 102000016267 Leptin Human genes 0.000 description 3
- 108010092277 Leptin Proteins 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 3
- HHJYYZJLRNLUIF-UHFFFAOYSA-N [4-(trifluoromethoxy)phenoxy]boronic acid Chemical compound OB(O)OC1=CC=C(OC(F)(F)F)C=C1 HHJYYZJLRNLUIF-UHFFFAOYSA-N 0.000 description 3
- 229960002632 acarbose Drugs 0.000 description 3
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 238000003016 alphascreen Methods 0.000 description 3
- 229940125708 antidiabetic agent Drugs 0.000 description 3
- 239000002220 antihypertensive agent Substances 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Chemical group 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 229940043279 diisopropylamine Drugs 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- RRYJRGXPFSRDHI-UHFFFAOYSA-N ethyl 5-(hydroxymethyl)thiophene-2-carboxylate Chemical compound CCOC(=O)C1=CC=C(CO)S1 RRYJRGXPFSRDHI-UHFFFAOYSA-N 0.000 description 3
- 238000002825 functional assay Methods 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 102000056448 human GLP1R Human genes 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 3
- 229940039781 leptin Drugs 0.000 description 3
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- GLZVUHUOFGLLMV-UHFFFAOYSA-N methyl 3-[[5-[1-(4-iodo-3,5-dimethylphenoxy)-2-methylpropyl]thiophene-2-carbonyl]amino]propanoate Chemical compound S1C(C(=O)NCCC(=O)OC)=CC=C1C(C(C)C)OC1=CC(C)=C(I)C(C)=C1 GLZVUHUOFGLLMV-UHFFFAOYSA-N 0.000 description 3
- QKASJXPIGANXRC-UHFFFAOYSA-N methyl 3-[[5-[1-[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenoxy]propyl]thiophene-2-carbonyl]amino]propanoate Chemical compound C=1C=C(C(=O)NCCC(=O)OC)SC=1C(CC)OC(C=C1C)=CC(C)=C1C1=CC=C(C(F)(F)F)C=C1 QKASJXPIGANXRC-UHFFFAOYSA-N 0.000 description 3
- ASHUHFCOOSBIOQ-UHFFFAOYSA-N methyl 3-[[5-[1-[4-(4-ethylphenyl)-3,5-dimethylphenoxy]-4,4,4-trifluorobutyl]thiophene-2-carbonyl]amino]propanoate Chemical compound C1=CC(CC)=CC=C1C(C(=C1)C)=C(C)C=C1OC(CCC(F)(F)F)C1=CC=C(C(=O)NCCC(=O)OC)S1 ASHUHFCOOSBIOQ-UHFFFAOYSA-N 0.000 description 3
- BYNHEZIZRRVVEE-UHFFFAOYSA-N methyl 3-[[5-[1-[4-(4-tert-butylphenyl)-3,5-dimethylphenoxy]propyl]thiophene-2-carbonyl]amino]propanoate Chemical compound C=1C=C(C(=O)NCCC(=O)OC)SC=1C(CC)OC(C=C1C)=CC(C)=C1C1=CC=C(C(C)(C)C)C=C1 BYNHEZIZRRVVEE-UHFFFAOYSA-N 0.000 description 3
- MTZIALLMVMKPKD-UHFFFAOYSA-N methyl 3-[[5-[1-[4-[4-(trifluoromethyl)phenyl]phenoxy]octyl]thiophene-2-carbonyl]amino]propanoate Chemical compound C=1C=C(C(=O)NCCC(=O)OC)SC=1C(CCCCCCC)OC(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 MTZIALLMVMKPKD-UHFFFAOYSA-N 0.000 description 3
- JVZCOTLDSAITIW-UHFFFAOYSA-N methyl 3-[[5-[4,4,4-trifluoro-1-(4-iodo-3,5-dimethylphenoxy)butyl]thiophene-2-carbonyl]amino]propanoate Chemical compound S1C(C(=O)NCCC(=O)OC)=CC=C1C(CCC(F)(F)F)OC1=CC(C)=C(I)C(C)=C1 JVZCOTLDSAITIW-UHFFFAOYSA-N 0.000 description 3
- SAZYLTAIRLAVSU-UHFFFAOYSA-N methyl 5-[1-[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenoxy]-2-methylpropan-2-yl]thiophene-2-carboxylate Chemical compound S1C(C(=O)OC)=CC=C1C(C)(C)COC1=CC(C)=C(C=2C=CC(=CC=2)C(F)(F)F)C(C)=C1 SAZYLTAIRLAVSU-UHFFFAOYSA-N 0.000 description 3
- ZZCGDQGSNGPPBQ-UHFFFAOYSA-N methyl 5-acetylthiophene-2-carboxylate Chemical compound COC(=O)C1=CC=C(C(C)=O)S1 ZZCGDQGSNGPPBQ-UHFFFAOYSA-N 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 239000000813 peptide hormone Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 238000001525 receptor binding assay Methods 0.000 description 3
- 229960002354 repaglinide Drugs 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 3
- 229960001641 troglitazone Drugs 0.000 description 3
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 3
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N valeric aldehyde Natural products CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 3
- HSTQHBMADMFCKR-BRIWLPCBSA-N (2r)-3-[[5-[1-[4-(4-tert-butylphenyl)-3,5-dimethylphenoxy]-2-methylpropyl]thiophene-2-carbonyl]amino]-2-hydroxypropanoic acid Chemical compound C=1C=C(C(=O)NC[C@@H](O)C(O)=O)SC=1C(C(C)C)OC(C=C1C)=CC(C)=C1C1=CC=C(C(C)(C)C)C=C1 HSTQHBMADMFCKR-BRIWLPCBSA-N 0.000 description 2
- YITAERDJEQNELZ-UHFFFAOYSA-N (4-ethylphenoxy)boronic acid Chemical compound CCC1=CC=C(OB(O)O)C=C1 YITAERDJEQNELZ-UHFFFAOYSA-N 0.000 description 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 2
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 description 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 2
- FFEKJBVVAJTQST-WLHGVMLRSA-N (e)-but-2-enedioic acid;1,1-dimethyl-2-(2-morpholin-4-ylphenyl)guanidine Chemical compound OC(=O)\C=C\C(O)=O.CN(C)C(N)=NC1=CC=CC=C1N1CCOCC1 FFEKJBVVAJTQST-WLHGVMLRSA-N 0.000 description 2
- YFEWSLOTSDWSLO-UHFFFAOYSA-N 1,3-dimethyl-2-[4-(trifluoromethyl)phenyl]benzene Chemical group CC1=CC=CC(C)=C1C1=CC=C(C(F)(F)F)C=C1 YFEWSLOTSDWSLO-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- ROKZAMCDHKVZIQ-UHFFFAOYSA-N 1-bromo-3,3-dimethylbutane Chemical compound CC(C)(C)CCBr ROKZAMCDHKVZIQ-UHFFFAOYSA-N 0.000 description 2
- ZQXCQTAELHSNAT-UHFFFAOYSA-N 1-chloro-3-nitro-5-(trifluoromethyl)benzene Chemical group [O-][N+](=O)C1=CC(Cl)=CC(C(F)(F)F)=C1 ZQXCQTAELHSNAT-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 2
- UXCJRTFEICXOFI-UHFFFAOYSA-N 3-[[5-[1-[3,5-dimethyl-4-(4-propan-2-ylphenyl)phenoxy]-4,4,4-trifluorobutyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C1=CC(C(C)C)=CC=C1C(C(=C1)C)=C(C)C=C1OC(CCC(F)(F)F)C1=CC=C(C(=O)NCCC(O)=O)S1 UXCJRTFEICXOFI-UHFFFAOYSA-N 0.000 description 2
- OZQOIPURVUOISF-UHFFFAOYSA-N 3-[[5-[1-[3,5-dimethyl-4-(4-propan-2-ylphenyl)phenoxy]butyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)SC=1C(CCC)OC(C=C1C)=CC(C)=C1C1=CC=C(C(C)C)C=C1 OZQOIPURVUOISF-UHFFFAOYSA-N 0.000 description 2
- VYDGIRDBHPIZAK-UHFFFAOYSA-N 3-[[5-[1-[3,5-dimethyl-4-[4-(trifluoromethoxy)phenyl]phenoxy]-2-methylpropyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)SC=1C(C(C)C)OC(C=C1C)=CC(C)=C1C1=CC=C(OC(F)(F)F)C=C1 VYDGIRDBHPIZAK-UHFFFAOYSA-N 0.000 description 2
- IPFANEDPBXBCPU-UHFFFAOYSA-N 3-[[5-[1-[3,5-dimethyl-4-[4-(trifluoromethoxy)phenyl]phenoxy]-4,4,4-trifluorobutyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C(C)=C(C=2C=CC(OC(F)(F)F)=CC=2)C(C)=CC=1OC(CCC(F)(F)F)C1=CC=C(C(=O)NCCC(O)=O)S1 IPFANEDPBXBCPU-UHFFFAOYSA-N 0.000 description 2
- CXMVWHKNFOLIIK-UHFFFAOYSA-N 3-[[5-[1-[3,5-dimethyl-4-[4-(trifluoromethoxy)phenyl]phenoxy]butyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)SC=1C(CCC)OC(C=C1C)=CC(C)=C1C1=CC=C(OC(F)(F)F)C=C1 CXMVWHKNFOLIIK-UHFFFAOYSA-N 0.000 description 2
- LAKWFKUDWXGYKE-UHFFFAOYSA-N 3-[[5-[1-[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenoxy]-2-methylpropyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)SC=1C(C(C)C)OC(C=C1C)=CC(C)=C1C1=CC=C(C(F)(F)F)C=C1 LAKWFKUDWXGYKE-UHFFFAOYSA-N 0.000 description 2
- MYFNNVOCKSNBEC-UHFFFAOYSA-N 3-[[5-[1-[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenoxy]-4,4,4-trifluorobutyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C(C)=C(C=2C=CC(=CC=2)C(F)(F)F)C(C)=CC=1OC(CCC(F)(F)F)C1=CC=C(C(=O)NCCC(O)=O)S1 MYFNNVOCKSNBEC-UHFFFAOYSA-N 0.000 description 2
- PUPHPJVLDGGHTL-UHFFFAOYSA-N 3-[[5-[1-[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenoxy]butan-2-yl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)SC=1C(CC)COC(C=C1C)=CC(C)=C1C1=CC=C(C(F)(F)F)C=C1 PUPHPJVLDGGHTL-UHFFFAOYSA-N 0.000 description 2
- UMSVMLGZMACEBC-UHFFFAOYSA-N 3-[[5-[1-[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenoxy]butyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)SC=1C(CCC)OC(C=C1C)=CC(C)=C1C1=CC=C(C(F)(F)F)C=C1 UMSVMLGZMACEBC-UHFFFAOYSA-N 0.000 description 2
- FICPSBRLJWJHCC-UHFFFAOYSA-N 3-[[5-[1-[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenoxy]pentyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)SC=1C(CCCC)OC(C=C1C)=CC(C)=C1C1=CC=C(C(F)(F)F)C=C1 FICPSBRLJWJHCC-UHFFFAOYSA-N 0.000 description 2
- WCXQNEUANFDWMO-UHFFFAOYSA-N 3-[[5-[1-[4-(4-ethylphenyl)-3,5-dimethylphenoxy]-4,4,4-trifluorobutyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C1=CC(CC)=CC=C1C(C(=C1)C)=C(C)C=C1OC(CCC(F)(F)F)C1=CC=C(C(=O)NCCC(O)=O)S1 WCXQNEUANFDWMO-UHFFFAOYSA-N 0.000 description 2
- SJACMFJFHKBAPA-UHFFFAOYSA-N 3-[[5-[1-[4-(4-tert-butylphenyl)-3,5-dimethylphenoxy]-2-methylpropyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)SC=1C(C(C)C)OC(C=C1C)=CC(C)=C1C1=CC=C(C(C)(C)C)C=C1 SJACMFJFHKBAPA-UHFFFAOYSA-N 0.000 description 2
- VZVSCVBIAZUPCS-UHFFFAOYSA-N 3-[[5-[1-[4-(4-tert-butylphenyl)-3,5-dimethylphenoxy]-4,4,4-trifluorobutyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C(C)=C(C=2C=CC(=CC=2)C(C)(C)C)C(C)=CC=1OC(CCC(F)(F)F)C1=CC=C(C(=O)NCCC(O)=O)S1 VZVSCVBIAZUPCS-UHFFFAOYSA-N 0.000 description 2
- LGJNFYPXUZNCQR-UHFFFAOYSA-N 3-[[5-[1-[4-(4-tert-butylphenyl)-3,5-dimethylphenoxy]butan-2-yl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)SC=1C(CC)COC(C=C1C)=CC(C)=C1C1=CC=C(C(C)(C)C)C=C1 LGJNFYPXUZNCQR-UHFFFAOYSA-N 0.000 description 2
- GENKWRUCNAWRRW-UHFFFAOYSA-N 3-[[5-[1-[4-(4-tert-butylphenyl)-3,5-dimethylphenoxy]butyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)SC=1C(CCC)OC(C=C1C)=CC(C)=C1C1=CC=C(C(C)(C)C)C=C1 GENKWRUCNAWRRW-UHFFFAOYSA-N 0.000 description 2
- IPWGCHBBVBSTMX-UHFFFAOYSA-N 3-[[5-[1-[4-(4-tert-butylphenyl)-3,5-dimethylphenyl]sulfanyl-2,2-dimethylpropyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C(C)=C(C=2C=CC(=CC=2)C(C)(C)C)C(C)=CC=1SC(C(C)(C)C)C1=CC=C(C(=O)NCCC(O)=O)S1 IPWGCHBBVBSTMX-UHFFFAOYSA-N 0.000 description 2
- CMGXNASZNOYFSD-UHFFFAOYSA-N 3-[[5-[1-[4-(4-tert-butylphenyl)-3,5-dimethylphenyl]sulfanylpropyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)SC=1C(CC)SC(C=C1C)=CC(C)=C1C1=CC=C(C(C)(C)C)C=C1 CMGXNASZNOYFSD-UHFFFAOYSA-N 0.000 description 2
- CQDMQHWMNMGXHP-UHFFFAOYSA-N 3-[[5-[1-[4-(4-tert-butylphenyl)-3-methylphenoxy]-2-methylpropyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)SC=1C(C(C)C)OC(C=C1C)=CC=C1C1=CC=C(C(C)(C)C)C=C1 CQDMQHWMNMGXHP-UHFFFAOYSA-N 0.000 description 2
- NDGGTZKMBDQZKO-UHFFFAOYSA-N 3-[[5-[1-[4-(4-tert-butylphenyl)-3-methylphenoxy]butyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)SC=1C(CCC)OC(C=C1C)=CC=C1C1=CC=C(C(C)(C)C)C=C1 NDGGTZKMBDQZKO-UHFFFAOYSA-N 0.000 description 2
- LEWWKXWBJPKBLV-UHFFFAOYSA-N 3-[[5-[1-[4-(4-tert-butylphenyl)-3-methylphenoxy]propyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)SC=1C(CC)OC(C=C1C)=CC=C1C1=CC=C(C(C)(C)C)C=C1 LEWWKXWBJPKBLV-UHFFFAOYSA-N 0.000 description 2
- KVFUYZIJZORGLT-UHFFFAOYSA-N 3-[[5-[1-[4-[4-(trifluoromethyl)phenyl]phenoxy]butyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)SC=1C(CCC)OC(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 KVFUYZIJZORGLT-UHFFFAOYSA-N 0.000 description 2
- FLIGKHIWZIMTCA-UHFFFAOYSA-N 3-[[5-[1-[4-[4-(trifluoromethyl)phenyl]phenoxy]propyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)SC=1C(CC)OC(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 FLIGKHIWZIMTCA-UHFFFAOYSA-N 0.000 description 2
- GDVBHWUWNDHOIO-UHFFFAOYSA-N 3-[[5-[2,2-dimethyl-1-[4-[4-(trifluoromethyl)phenyl]phenoxy]propyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)SC=1C(C(C)(C)C)OC(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 GDVBHWUWNDHOIO-UHFFFAOYSA-N 0.000 description 2
- CFZRDDYTXVITQI-UHFFFAOYSA-N 3-[[5-[3,3-dimethyl-1-[4-[4-(trifluoromethyl)phenyl]phenoxy]butyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)SC=1C(CC(C)(C)C)OC(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 CFZRDDYTXVITQI-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 2
- IDWBFMSDALIZNU-UHFFFAOYSA-N 5-[1-[[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenoxy]methyl]cyclopent-3-en-1-yl]thiophene-2-carboxylic acid Chemical compound C=1C(C)=C(C=2C=CC(=CC=2)C(F)(F)F)C(C)=CC=1OCC1(C=2SC(=CC=2)C(O)=O)CC=CC1 IDWBFMSDALIZNU-UHFFFAOYSA-N 0.000 description 2
- KVCOOWROABTXDJ-UHFFFAOYSA-N 6-chloropyridin-3-ol Chemical compound OC1=CC=C(Cl)N=C1 KVCOOWROABTXDJ-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 229940122816 Amylase inhibitor Drugs 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 101800001982 Cholecystokinin Proteins 0.000 description 2
- 102100025841 Cholecystokinin Human genes 0.000 description 2
- 102100032165 Corticotropin-releasing factor-binding protein Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 102000001267 GSK3 Human genes 0.000 description 2
- 102000030595 Glucokinase Human genes 0.000 description 2
- 108010021582 Glucokinase Proteins 0.000 description 2
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 101500025568 Homo sapiens Saposin-D Proteins 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 108010057186 Insulin Glargine Proteins 0.000 description 2
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 2
- 229940122355 Insulin sensitizer Drugs 0.000 description 2
- AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 229940086609 Lipase inhibitor Drugs 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 108010008364 Melanocortins Proteins 0.000 description 2
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 2
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 2
- 101710151321 Melanostatin Proteins 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 102400000064 Neuropeptide Y Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102000004257 Potassium Channel Human genes 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- 229940123464 Thiazolidinedione Drugs 0.000 description 2
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000008219 Uncoupling Protein 2 Human genes 0.000 description 2
- 108010021111 Uncoupling Protein 2 Proteins 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000005466 alkylenyl group Chemical group 0.000 description 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 229940025084 amphetamine Drugs 0.000 description 2
- 239000003392 amylase inhibitor Substances 0.000 description 2
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 239000003524 antilipemic agent Substances 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000003130 blood coagulation factor inhibitor Substances 0.000 description 2
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 2
- 229960002802 bromocriptine Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229940107137 cholecystokinin Drugs 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000037011 constitutive activity Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 108010083720 corticotropin releasing factor-binding protein Proteins 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000003821 enantio-separation Methods 0.000 description 2
- QDXNIXXGKIXJDI-FPSALIRRSA-N ethyl (2r)-3-[[5-[1-[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenoxy]-2-methylpropyl]thiophene-2-carbonyl]amino]-2-hydroxypropanoate Chemical compound S1C(C(=O)NC[C@@H](O)C(=O)OCC)=CC=C1C(C(C)C)OC1=CC(C)=C(C=2C=CC(=CC=2)C(F)(F)F)C(C)=C1 QDXNIXXGKIXJDI-FPSALIRRSA-N 0.000 description 2
- ZJZQFFICSFOEGQ-UHFFFAOYSA-N ethyl 5-(1-hydroxy-2-methylpropyl)thiophene-2-carboxylate Chemical compound CCOC(=O)C1=CC=C(C(O)C(C)C)S1 ZJZQFFICSFOEGQ-UHFFFAOYSA-N 0.000 description 2
- LHMILTDZUKBJJM-UHFFFAOYSA-N ethyl 5-(4,4,4-trifluoro-1-hydroxybutyl)thiophene-2-carboxylate Chemical compound CCOC(=O)C1=CC=C(C(O)CCC(F)(F)F)S1 LHMILTDZUKBJJM-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000004401 flow injection analysis Methods 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960001381 glipizide Drugs 0.000 description 2
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 230000003284 homeostatic effect Effects 0.000 description 2
- 239000011539 homogenization buffer Substances 0.000 description 2
- 229940100689 human protein c Drugs 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 150000002462 imidazolines Chemical class 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 239000004026 insulin derivative Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 229940057428 lactoperoxidase Drugs 0.000 description 2
- 229940060975 lantus Drugs 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 229950004994 meglitinide Drugs 0.000 description 2
- 239000002865 melanocortin Substances 0.000 description 2
- 230000006371 metabolic abnormality Effects 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- NIUUJCNUOJQDIA-JGKWMGOWSA-N methyl (2r)-3-[[5-[1-[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenoxy]-2-methylpropyl]thiophene-2-carbonyl]amino]-2-hydroxypropanoate Chemical compound S1C(C(=O)NC[C@@H](O)C(=O)OC)=CC=C1C(C(C)C)OC1=CC(C)=C(C=2C=CC(=CC=2)C(F)(F)F)C(C)=C1 NIUUJCNUOJQDIA-JGKWMGOWSA-N 0.000 description 2
- YYBDTLYBEHESTG-UHFFFAOYSA-N methyl 2-ethyl-2-thiophen-2-ylbutanoate Chemical compound COC(=O)C(CC)(CC)C1=CC=CS1 YYBDTLYBEHESTG-UHFFFAOYSA-N 0.000 description 2
- LQNPPYHFNJTOOA-UHFFFAOYSA-N methyl 2-methyl-2-thiophen-2-ylpropanoate Chemical compound COC(=O)C(C)(C)C1=CC=CS1 LQNPPYHFNJTOOA-UHFFFAOYSA-N 0.000 description 2
- KNKIXYMOHMYZJR-UHFFFAOYSA-N methyl 2-thiophen-2-ylacetate Chemical compound COC(=O)CC1=CC=CS1 KNKIXYMOHMYZJR-UHFFFAOYSA-N 0.000 description 2
- QAVVENDFLSMMSW-UHFFFAOYSA-N methyl 3-[[5-[1-(4-bromo-3,5-dimethylphenyl)sulfanyl-4,4,4-trifluorobutyl]thiophene-2-carbonyl]amino]propanoate Chemical class S1C(C(=O)NCCC(=O)OC)=CC=C1C(CCC(F)(F)F)SC1=CC(C)=C(Br)C(C)=C1 QAVVENDFLSMMSW-UHFFFAOYSA-N 0.000 description 2
- SMHZMYQGEBIYQN-UHFFFAOYSA-N methyl 3-[[5-[1-[3,5-dimethyl-4-(4-propan-2-ylphenyl)phenoxy]-2-methylpropyl]thiophene-2-carbonyl]amino]propanoate Chemical compound S1C(C(=O)NCCC(=O)OC)=CC=C1C(C(C)C)OC1=CC(C)=C(C=2C=CC(=CC=2)C(C)C)C(C)=C1 SMHZMYQGEBIYQN-UHFFFAOYSA-N 0.000 description 2
- HQWGYOFIMAETER-UHFFFAOYSA-N methyl 3-[[5-[1-[3,5-dimethyl-4-(4-propan-2-ylphenyl)phenoxy]-4,4,4-trifluorobutyl]thiophene-2-carbonyl]amino]propanoate Chemical compound S1C(C(=O)NCCC(=O)OC)=CC=C1C(CCC(F)(F)F)OC1=CC(C)=C(C=2C=CC(=CC=2)C(C)C)C(C)=C1 HQWGYOFIMAETER-UHFFFAOYSA-N 0.000 description 2
- YXPVZFZWRPVBQE-UHFFFAOYSA-N methyl 3-[[5-[1-[3,5-dimethyl-4-[4-(trifluoromethoxy)phenyl]phenoxy]-4,4,4-trifluorobutyl]thiophene-2-carbonyl]amino]propanoate Chemical compound S1C(C(=O)NCCC(=O)OC)=CC=C1C(CCC(F)(F)F)OC1=CC(C)=C(C=2C=CC(OC(F)(F)F)=CC=2)C(C)=C1 YXPVZFZWRPVBQE-UHFFFAOYSA-N 0.000 description 2
- FBMLACQPWXNBIK-UHFFFAOYSA-N methyl 3-[[5-[1-[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenoxy]-2-methylpropyl]thiophene-2-carbonyl]amino]propanoate Chemical compound S1C(C(=O)NCCC(=O)OC)=CC=C1C(C(C)C)OC1=CC(C)=C(C=2C=CC(=CC=2)C(F)(F)F)C(C)=C1 FBMLACQPWXNBIK-UHFFFAOYSA-N 0.000 description 2
- BLZQUFKMUXSTJN-UHFFFAOYSA-N methyl 3-[[5-[1-[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenoxy]-3,3-dimethylbutyl]thiophene-2-carbonyl]amino]propanoate Chemical compound S1C(C(=O)NCCC(=O)OC)=CC=C1C(CC(C)(C)C)OC1=CC(C)=C(C=2C=CC(=CC=2)C(F)(F)F)C(C)=C1 BLZQUFKMUXSTJN-UHFFFAOYSA-N 0.000 description 2
- ZBOLZXQODPYHGT-UHFFFAOYSA-N methyl 3-[[5-[1-[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenoxy]pentyl]thiophene-2-carbonyl]amino]propanoate Chemical compound C=1C=C(C(=O)NCCC(=O)OC)SC=1C(CCCC)OC(C=C1C)=CC(C)=C1C1=CC=C(C(F)(F)F)C=C1 ZBOLZXQODPYHGT-UHFFFAOYSA-N 0.000 description 2
- CHGOSUXWQIKXQH-UHFFFAOYSA-N methyl 3-[[5-[1-[4-(4-tert-butylphenyl)-3,5-dimethylphenoxy]butyl]thiophene-2-carbonyl]amino]propanoate Chemical compound C=1C=C(C(=O)NCCC(=O)OC)SC=1C(CCC)OC(C=C1C)=CC(C)=C1C1=CC=C(C(C)(C)C)C=C1 CHGOSUXWQIKXQH-UHFFFAOYSA-N 0.000 description 2
- LUGFFRXKYJUDGR-UHFFFAOYSA-N methyl 3-[[5-[1-[4-(4-tert-butylphenyl)-3,5-dimethylphenoxy]ethyl]thiophene-2-carbonyl]amino]propanoate Chemical compound S1C(C(=O)NCCC(=O)OC)=CC=C1C(C)OC1=CC(C)=C(C=2C=CC(=CC=2)C(C)(C)C)C(C)=C1 LUGFFRXKYJUDGR-UHFFFAOYSA-N 0.000 description 2
- ORIHPFXMLUTDGE-UHFFFAOYSA-N methyl 3-[[5-[1-[4-(4-tert-butylphenyl)-3,5-dimethylphenyl]sulfanyl-4,4,4-trifluorobutyl]thiophene-2-carbonyl]amino]propanoate Chemical compound S1C(C(=O)NCCC(=O)OC)=CC=C1C(CCC(F)(F)F)SC1=CC(C)=C(C=2C=CC(=CC=2)C(C)(C)C)C(C)=C1 ORIHPFXMLUTDGE-UHFFFAOYSA-N 0.000 description 2
- FXEBISFIMGUPNE-UHFFFAOYSA-N methyl 3-[[5-[1-[4-(4-tert-butylphenyl)-3-methylphenoxy]butyl]thiophene-2-carbonyl]amino]propanoate Chemical compound C=1C=C(C(=O)NCCC(=O)OC)SC=1C(CCC)OC(C=C1C)=CC=C1C1=CC=C(C(C)(C)C)C=C1 FXEBISFIMGUPNE-UHFFFAOYSA-N 0.000 description 2
- PIZYXZSOQQXLGJ-UHFFFAOYSA-N methyl 3-[[5-[1-[4-(4-tert-butylphenyl)-3-methylphenoxy]propyl]thiophene-2-carbonyl]amino]propanoate Chemical compound C=1C=C(C(=O)NCCC(=O)OC)SC=1C(CC)OC(C=C1C)=CC=C1C1=CC=C(C(C)(C)C)C=C1 PIZYXZSOQQXLGJ-UHFFFAOYSA-N 0.000 description 2
- RQSHVMYHFFFPNQ-UHFFFAOYSA-N methyl 3-[[5-[1-[4-[4-(trifluoromethyl)phenyl]phenoxy]butyl]thiophene-2-carbonyl]amino]propanoate Chemical compound C=1C=C(C(=O)NCCC(=O)OC)SC=1C(CCC)OC(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 RQSHVMYHFFFPNQ-UHFFFAOYSA-N 0.000 description 2
- JDGVQKNQROLGRV-UHFFFAOYSA-N methyl 3-[[5-[1-[4-[4-(trifluoromethyl)phenyl]phenoxy]propyl]thiophene-2-carbonyl]amino]propanoate Chemical compound C=1C=C(C(=O)NCCC(=O)OC)SC=1C(CC)OC(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 JDGVQKNQROLGRV-UHFFFAOYSA-N 0.000 description 2
- XTPLAYPTEVKCMN-UHFFFAOYSA-N methyl 3-[[5-[2,2-dimethyl-1-[3-methyl-4-[4-(trifluoromethyl)phenyl]phenoxy]propyl]thiophene-2-carbonyl]amino]propanoate Chemical compound S1C(C(=O)NCCC(=O)OC)=CC=C1C(C(C)(C)C)OC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C(C)=C1 XTPLAYPTEVKCMN-UHFFFAOYSA-N 0.000 description 2
- GEJNHERSNGRKMX-UHFFFAOYSA-N methyl 3-[[5-[2,2-dimethyl-1-[4-[4-(trifluoromethyl)phenyl]phenoxy]propyl]thiophene-2-carbonyl]amino]propanoate Chemical compound S1C(C(=O)NCCC(=O)OC)=CC=C1C(C(C)(C)C)OC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 GEJNHERSNGRKMX-UHFFFAOYSA-N 0.000 description 2
- OLEMQNDHSDVAMZ-UHFFFAOYSA-N methyl 3-[[5-[2-methyl-1-[4-[4-(trifluoromethyl)phenyl]phenoxy]propyl]thiophene-2-carbonyl]amino]propanoate Chemical compound S1C(C(=O)NCCC(=O)OC)=CC=C1C(C(C)C)OC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 OLEMQNDHSDVAMZ-UHFFFAOYSA-N 0.000 description 2
- MNAIVRBRXSYEQL-UHFFFAOYSA-N methyl 3-[[5-[3,3-dimethyl-1-[4-[4-(trifluoromethyl)phenyl]phenoxy]butyl]thiophene-2-carbonyl]amino]propanoate Chemical compound S1C(C(=O)NCCC(=O)OC)=CC=C1C(CC(C)(C)C)OC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 MNAIVRBRXSYEQL-UHFFFAOYSA-N 0.000 description 2
- IEGGJVWHEMJKSG-UHFFFAOYSA-N methyl 3-[[5-[3-[[4-(4-tert-butylphenyl)-3,5-dimethylphenoxy]methyl]pentan-3-yl]thiophene-2-carbonyl]amino]propanoate Chemical compound C=1C=C(C(=O)NCCC(=O)OC)SC=1C(CC)(CC)COC(C=C1C)=CC(C)=C1C1=CC=C(C(C)(C)C)C=C1 IEGGJVWHEMJKSG-UHFFFAOYSA-N 0.000 description 2
- UZCXPYDBYUEZCV-UHFFFAOYSA-N methyl 3-aminopropanoate Chemical compound COC(=O)CCN UZCXPYDBYUEZCV-UHFFFAOYSA-N 0.000 description 2
- WQNPDJOZZAOOAY-UHFFFAOYSA-N methyl 4-chloro-5-(1-hydroxypropyl)thiophene-2-carboxylate Chemical compound CCC(O)C=1SC(C(=O)OC)=CC=1Cl WQNPDJOZZAOOAY-UHFFFAOYSA-N 0.000 description 2
- FOQFEFVQOXUKHM-UHFFFAOYSA-N methyl 5-(1-hydroxybutan-2-yl)thiophene-2-carboxylate Chemical compound CCC(CO)C1=CC=C(C(=O)OC)S1 FOQFEFVQOXUKHM-UHFFFAOYSA-N 0.000 description 2
- SFNPRHBRZHTZJP-UHFFFAOYSA-N methyl 5-[1-[[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenoxy]methyl]cyclopent-3-en-1-yl]thiophene-2-carboxylate Chemical compound S1C(C(=O)OC)=CC=C1C1(COC=2C=C(C)C(=C(C)C=2)C=2C=CC(=CC=2)C(F)(F)F)CC=CC1 SFNPRHBRZHTZJP-UHFFFAOYSA-N 0.000 description 2
- LIYBFEWITUNBOZ-UHFFFAOYSA-N methyl 5-[3-[[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenoxy]methyl]pentan-3-yl]thiophene-2-carboxylate Chemical compound C=1C=C(C(=O)OC)SC=1C(CC)(CC)COC(C=C1C)=CC(C)=C1C1=CC=C(C(F)(F)F)C=C1 LIYBFEWITUNBOZ-UHFFFAOYSA-N 0.000 description 2
- AFBBKFYLCJPGJC-UHFFFAOYSA-N methyl 5-[4-[[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenoxy]methyl]hepta-1,6-dien-4-yl]thiophene-2-carboxylate Chemical compound S1C(C(=O)OC)=CC=C1C(CC=C)(CC=C)COC1=CC(C)=C(C=2C=CC(=CC=2)C(F)(F)F)C(C)=C1 AFBBKFYLCJPGJC-UHFFFAOYSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 2
- 229960003086 naltrexone Drugs 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 2
- NUJGJRNETVAIRJ-UHFFFAOYSA-N octanal Chemical compound CCCCCCCC=O NUJGJRNETVAIRJ-UHFFFAOYSA-N 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 239000003614 peroxisome proliferator Substances 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 108020001213 potassium channel Proteins 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 2
- 229960003015 rimonabant Drugs 0.000 description 2
- 238000002821 scintillation proximity assay Methods 0.000 description 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- 229960005371 tolbutamide Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- CNHDIAIOKMXOLK-UHFFFAOYSA-N toluquinol Chemical compound CC1=CC(O)=CC=C1O CNHDIAIOKMXOLK-UHFFFAOYSA-N 0.000 description 2
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 2
- 125000000725 trifluoropropyl group Chemical group [H]C([H])(*)C([H])([H])C(F)(F)F 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical group CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- WMUIIGVAWPWQAW-XMMPIXPASA-N (2r)-2-ethoxy-3-[4-(2-phenoxazin-10-ylethoxy)phenyl]propanoic acid Chemical compound C1=CC(C[C@@H](OCC)C(O)=O)=CC=C1OCCN1C2=CC=CC=C2OC2=CC=CC=C21 WMUIIGVAWPWQAW-XMMPIXPASA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- UMRUUWFGLGNQLI-QFIPXVFZSA-M (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoate Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C([O-])=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-M 0.000 description 1
- QNDFBOXBUCDYNZ-NRFANRHFSA-N (2s)-2-ethoxy-3-[4-[2-[4-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]ethoxy]phenyl]propanoic acid Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCC1=CC=C(NC(=O)OC(C)(C)C)C=C1 QNDFBOXBUCDYNZ-NRFANRHFSA-N 0.000 description 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- FIPZWVLCZIYEMW-UHFFFAOYSA-N (4-cyanophenoxy)boronic acid Chemical compound OB(O)OC1=CC=C(C#N)C=C1 FIPZWVLCZIYEMW-UHFFFAOYSA-N 0.000 description 1
- BIWQNIMLAISTBV-UHFFFAOYSA-N (4-methylphenyl)boronic acid Chemical compound CC1=CC=C(B(O)O)C=C1 BIWQNIMLAISTBV-UHFFFAOYSA-N 0.000 description 1
- AMHMDVGINXZDHQ-UHFFFAOYSA-N (5-acetylthiophen-2-yl)oxyboronic acid Chemical compound CC(=O)C1=CC=C(OB(O)O)S1 AMHMDVGINXZDHQ-UHFFFAOYSA-N 0.000 description 1
- DMJWENQHWZZWDF-PKOBYXMFSA-N (6aS,13bR)-11-chloro-7-methyl-5,6,6a,8,9,13b-hexahydronaphtho[1,2-a][3]benzazepin-12-ol Chemical compound CN1CCC2=CC(Cl)=C(O)C=C2[C@H]2C3=CC=CC=C3CC[C@H]12 DMJWENQHWZZWDF-PKOBYXMFSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- FWBDUAPLKFBELK-UHFFFAOYSA-N 1-fluoro-2-nitro-4-phenylmethoxybenzene Chemical compound C1=C(F)C([N+](=O)[O-])=CC(OCC=2C=CC=CC=2)=C1 FWBDUAPLKFBELK-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- OUMKBAHMPRLISR-UHFFFAOYSA-N 1-phenyl-4-(trifluoromethyl)benzene Chemical group C1=CC(C(F)(F)F)=CC=C1C1=CC=CC=C1 OUMKBAHMPRLISR-UHFFFAOYSA-N 0.000 description 1
- 102000004277 11-beta-hydroxysteroid dehydrogenases Human genes 0.000 description 1
- 108090000874 11-beta-hydroxysteroid dehydrogenases Proteins 0.000 description 1
- RVXSASLSNHDASC-OSWDIKPLSA-N 110084-95-2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CO)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 RVXSASLSNHDASC-OSWDIKPLSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- LVNVLQIXMBTMPH-UHFFFAOYSA-N 2,3-dichlorothiophene Chemical compound ClC=1C=CSC=1Cl LVNVLQIXMBTMPH-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- LUACLLSCZRRTIH-UPHRSURJSA-N 2-[[4-[(z)-4-[4-[(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)methyl]phenoxy]but-2-enoxy]phenyl]methyl]-1,2,4-oxadiazolidine-3,5-dione Chemical compound O1C(=O)NC(=O)N1CC(C=C1)=CC=C1OC\C=C/COC(C=C1)=CC=C1CN1C(=O)NC(=O)O1 LUACLLSCZRRTIH-UPHRSURJSA-N 0.000 description 1
- BJBCSGQLZQGGIQ-QGZVFWFLSA-N 2-acetamidoethyl (2r)-2-(4-chlorophenyl)-2-[3-(trifluoromethyl)phenoxy]acetate Chemical compound O([C@@H](C(=O)OCCNC(=O)C)C=1C=CC(Cl)=CC=1)C1=CC=CC(C(F)(F)F)=C1 BJBCSGQLZQGGIQ-QGZVFWFLSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- RJRCNQDYNGJKDV-UHFFFAOYSA-N 2-ethyl-2-thiophen-2-ylbutan-1-ol Chemical compound CCC(CC)(CO)C1=CC=CS1 RJRCNQDYNGJKDV-UHFFFAOYSA-N 0.000 description 1
- AUVALWUPUHHNQV-UHFFFAOYSA-N 2-hydroxy-3-propylbenzoic acid Chemical compound CCCC1=CC=CC(C(O)=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-N 0.000 description 1
- IRJPDCQBUPZLAX-UHFFFAOYSA-N 2-methyl-2-thiophen-2-ylpropan-1-ol Chemical compound OCC(C)(C)C1=CC=CS1 IRJPDCQBUPZLAX-UHFFFAOYSA-N 0.000 description 1
- KSLMTVJQCZHFOA-UHFFFAOYSA-N 3,5-dimethyl-4-(4-propan-2-ylphenyl)benzenethiol Chemical compound C1=CC(C(C)C)=CC=C1C1=C(C)C=C(S)C=C1C KSLMTVJQCZHFOA-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- GLUHJDYSHVBDNJ-UHFFFAOYSA-N 3-[1-[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenyl]sulfanyl-2-methylpropyl]thiophene-2-carboxylic acid Chemical compound CC1=C(C(=CC(=C1)SC(C(C)C)C1=C(SC=C1)C(=O)O)C)C1=CC=C(C=C1)C(F)(F)F GLUHJDYSHVBDNJ-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
- CITGBTPFGOEGNA-UHFFFAOYSA-N 3-[[5-[1-(4-bromo-3,5-dimethylphenoxy)-3-methylbutyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)SC=1C(CC(C)C)OC1=CC(C)=C(Br)C(C)=C1 CITGBTPFGOEGNA-UHFFFAOYSA-N 0.000 description 1
- WESNADSNJTYRQU-UHFFFAOYSA-N 3-[[5-[1-[3,5-dimethyl-4-(4-propan-2-ylphenyl)phenoxy]-2-methylpropyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)SC=1C(C(C)C)OC(C=C1C)=CC(C)=C1C1=CC=C(C(C)C)C=C1 WESNADSNJTYRQU-UHFFFAOYSA-N 0.000 description 1
- GKWOBNLNCHYZJY-UHFFFAOYSA-N 3-[[5-[1-[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenyl]sulfanylpentyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)SC=1C(CCCC)SC(C=C1C)=CC(C)=C1C1=CC=C(C(F)(F)F)C=C1 GKWOBNLNCHYZJY-UHFFFAOYSA-N 0.000 description 1
- QCGYYBKKJWCUCA-UHFFFAOYSA-N 3-[[5-[1-[4-(4-tert-butylphenyl)-3,5-dimethylphenyl]sulfanyl-3,3-dimethylbutyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C(C)=C(C=2C=CC(=CC=2)C(C)(C)C)C(C)=CC=1SC(CC(C)(C)C)C1=CC=C(C(=O)NCCC(O)=O)S1 QCGYYBKKJWCUCA-UHFFFAOYSA-N 0.000 description 1
- BZWRHHLTTOVYEN-UHFFFAOYSA-N 3-[[5-[1-[[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenoxy]methyl]cyclopentyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C(C)=C(C=2C=CC(=CC=2)C(F)(F)F)C(C)=CC=1OCC1(C=2SC(=CC=2)C(=O)NCCC(O)=O)CCCC1 BZWRHHLTTOVYEN-UHFFFAOYSA-N 0.000 description 1
- MRLRXKYCSHVZQP-UHFFFAOYSA-N 3-[[5-[2-[4-(4-tert-butylphenyl)-3,5-dimethylphenyl]sulfanylpropan-2-yl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C(C)=C(C=2C=CC(=CC=2)C(C)(C)C)C(C)=CC=1SC(C)(C)C1=CC=C(C(=O)NCCC(O)=O)S1 MRLRXKYCSHVZQP-UHFFFAOYSA-N 0.000 description 1
- DLVHUQZTBDEKPB-UHFFFAOYSA-N 3-[[5-[2-methyl-1-[4-[4-(trifluoromethyl)phenyl]phenoxy]propyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)SC=1C(C(C)C)OC(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 DLVHUQZTBDEKPB-UHFFFAOYSA-N 0.000 description 1
- IQUYQYPJQRZOOO-UHFFFAOYSA-N 3-[[5-[4,4,4-trifluoro-1-(4-iodo-3,5-dimethylphenoxy)butyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound FC(CCC(OC1=CC(=C(C(=C1)C)I)C)C1=CC=C(S1)C(=O)NCCC(=O)O)(F)F IQUYQYPJQRZOOO-UHFFFAOYSA-N 0.000 description 1
- DRJFPKSHFDNDBL-UHFFFAOYSA-N 3-[[5-[[4-(4-tert-butylphenyl)-3,5-dimethylphenoxy]methyl]thiophene-2-carbonyl]amino]propanoic acid Chemical compound C=1C(C)=C(C=2C=CC(=CC=2)C(C)(C)C)C(C)=CC=1OCC1=CC=C(C(=O)NCCC(O)=O)S1 DRJFPKSHFDNDBL-UHFFFAOYSA-N 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- XPSIVWGPYKWZDL-UHFFFAOYSA-N 4,4,4-trifluoro-3-methylbutanal Chemical compound FC(F)(F)C(C)CC=O XPSIVWGPYKWZDL-UHFFFAOYSA-N 0.000 description 1
- LGSOKZOQANLOEU-UHFFFAOYSA-N 4-[2-(2,4-dioxo-1,3-thiazolidin-5-yl)ethoxy]benzonitrile Chemical compound S1C(=O)NC(=O)C1CCOC1=CC=C(C#N)C=C1 LGSOKZOQANLOEU-UHFFFAOYSA-N 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- QBQLYIISSRXYKL-UHFFFAOYSA-N 4-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,2-oxazolidine-3,5-dione Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCOC(C=C1)=CC=C1CC1C(=O)NOC1=O QBQLYIISSRXYKL-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- WMUWDPLTTLJNPE-UHFFFAOYSA-N 4-bromo-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Br WMUWDPLTTLJNPE-UHFFFAOYSA-N 0.000 description 1
- GPOQODYGMUTOQL-UHFFFAOYSA-N 4-bromo-3-methylphenol Chemical compound CC1=CC(O)=CC=C1Br GPOQODYGMUTOQL-UHFFFAOYSA-N 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- STQPFSVMEUMGEW-UHFFFAOYSA-N 5-(1-hydroxyethyl)thiophene-2-carboxylic acid Chemical compound CC(O)C1=CC=C(C(O)=O)S1 STQPFSVMEUMGEW-UHFFFAOYSA-N 0.000 description 1
- PJCNUJPGTNVVGB-UHFFFAOYSA-N 5-(4,4,4-trifluoro-1-hydroxybutyl)thiophene-2-carboxylic acid Chemical class FC(CCC(O)C1=CC=C(S1)C(=O)O)(F)F PJCNUJPGTNVVGB-UHFFFAOYSA-N 0.000 description 1
- XBGHLYFPQBIUHS-UHFFFAOYSA-N 5-[1-(4-bromo-3,5-dimethylphenoxy)-3-methylbutyl]thiophene-2-carboxylic acid Chemical compound C=1C=C(C(O)=O)SC=1C(CC(C)C)OC1=CC(C)=C(Br)C(C)=C1 XBGHLYFPQBIUHS-UHFFFAOYSA-N 0.000 description 1
- KSFTZHKNMOCOQT-UHFFFAOYSA-N 5-[1-(4-bromo-3,5-dimethylphenyl)sulfanyl-4,4,4-trifluorobutyl]thiophene-2-carboxylic acid Chemical compound CC1=C(Br)C(C)=CC(SC(CCC(F)(F)F)C=2SC(=CC=2)C(O)=O)=C1 KSFTZHKNMOCOQT-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- HJMPVORZRMQCCI-UHFFFAOYSA-N 5-[1-[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenoxy]-4,4,4-trifluorobutyl]thiophene-2-carboxylic acid Chemical compound C=1C(C)=C(C=2C=CC(=CC=2)C(F)(F)F)C(C)=CC=1OC(CCC(F)(F)F)C1=CC=C(C(O)=O)S1 HJMPVORZRMQCCI-UHFFFAOYSA-N 0.000 description 1
- POXITZMOPFZCDP-UHFFFAOYSA-N 5-[1-[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenoxy]ethyl]thiophene-2-carboxylic acid Chemical compound C=1C=C(C(O)=O)SC=1C(C)OC(C=C1C)=CC(C)=C1C1=CC=C(C(F)(F)F)C=C1 POXITZMOPFZCDP-UHFFFAOYSA-N 0.000 description 1
- GHHDWIPKLMPSGL-UHFFFAOYSA-N 5-[1-[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenyl]sulfanyl-2-methylpropyl]thiophene-2-carboxylic acid Chemical compound C=1C=C(C(O)=O)SC=1C(C(C)C)SC(C=C1C)=CC(C)=C1C1=CC=C(C(F)(F)F)C=C1 GHHDWIPKLMPSGL-UHFFFAOYSA-N 0.000 description 1
- HTEIUTIAJSLFQH-UHFFFAOYSA-N 5-[1-[4-(4-tert-butylphenyl)-3,5-dimethylphenoxy]-4,4,4-trifluorobutyl]thiophene-2-carboxylic acid Chemical compound C=1C(C)=C(C=2C=CC(=CC=2)C(C)(C)C)C(C)=CC=1OC(CCC(F)(F)F)C1=CC=C(C(O)=O)S1 HTEIUTIAJSLFQH-UHFFFAOYSA-N 0.000 description 1
- QSLSFSHDVRCKKM-UHFFFAOYSA-N 5-[1-[4-(4-tert-butylphenyl)-3,5-dimethylphenoxy]ethyl]thiophene-2-carboxylic acid Chemical compound C=1C=C(C(O)=O)SC=1C(C)OC(C=C1C)=CC(C)=C1C1=CC=C(C(C)(C)C)C=C1 QSLSFSHDVRCKKM-UHFFFAOYSA-N 0.000 description 1
- PJOUIGWXHQUNBK-UHFFFAOYSA-N 5-[3-(hydroxymethyl)pentan-3-yl]thiophene-2-carboxylic acid Chemical compound CCC(CC)(CO)C1=CC=C(C(O)=O)S1 PJOUIGWXHQUNBK-UHFFFAOYSA-N 0.000 description 1
- FAKVKSUJNDSJEG-UHFFFAOYSA-N 5-[4,4,4-trifluoro-1-(4-iodo-3,5-dimethylphenoxy)butyl]thiophene-2-carboxylic acid Chemical compound CC1=C(I)C(C)=CC(OC(CCC(F)(F)F)C=2SC(=CC=2)C(O)=O)=C1 FAKVKSUJNDSJEG-UHFFFAOYSA-N 0.000 description 1
- MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 description 1
- LKKAMJRUPIIUTC-UHFFFAOYSA-N 5-[[4-[(6-methoxy-1-methylbenzimidazol-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione;hydrochloride Chemical compound Cl.CN1C2=CC(OC)=CC=C2N=C1COC(C=C1)=CC=C1CC1SC(=O)NC1=O LKKAMJRUPIIUTC-UHFFFAOYSA-N 0.000 description 1
- LIKIMWYKJUFVJP-UHFFFAOYSA-N 5-acetylthiophene-2-carboxylic acid Chemical compound CC(=O)C1=CC=C(C(O)=O)S1 LIKIMWYKJUFVJP-UHFFFAOYSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- MWMKBKZQDAEUNK-UHFFFAOYSA-N 6-(4-tert-butylphenyl)pyridin-3-ol Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=CC=C(O)C=N1 MWMKBKZQDAEUNK-UHFFFAOYSA-N 0.000 description 1
- SLXTWXQUEZSSTJ-UHFFFAOYSA-N 6-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl]pyridine-3-carboxylic acid Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C1(C=2N=CC(=CC=2)C(O)=O)CC1 SLXTWXQUEZSSTJ-UHFFFAOYSA-N 0.000 description 1
- GJNHPHFWBJTBJK-UHFFFAOYSA-N 6-[4-(trifluoromethyl)phenyl]pyridin-3-ol Chemical compound N1=CC(O)=CC=C1C1=CC=C(C(F)(F)F)C=C1 GJNHPHFWBJTBJK-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 241000283726 Bison Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- YUBRSGFTVLSRAM-UHFFFAOYSA-N BrC1=C(C=C(C=C1C)O)C.CN(C(O)=S)C Chemical compound BrC1=C(C=C(C=C1C)O)C.CN(C(O)=S)C YUBRSGFTVLSRAM-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- UWLHBERSYHCCNP-UHFFFAOYSA-N C(#N)C1=CC=C(S1)OB(O)O Chemical compound C(#N)C1=CC=C(S1)OB(O)O UWLHBERSYHCCNP-UHFFFAOYSA-N 0.000 description 1
- KCCCHURIRRAKJC-UHFFFAOYSA-N C(C)(C)(C)C1=CC=C(C=C1)C1=C(C=C(C=C1C)O)C.CN(C(O)=S)C Chemical compound C(C)(C)(C)C1=CC=C(C=C1)C1=C(C=C(C=C1C)O)C.CN(C(O)=S)C KCCCHURIRRAKJC-UHFFFAOYSA-N 0.000 description 1
- VQKJMULJQOCYIU-UHFFFAOYSA-N C(C)C(CC)(CO)C1=CC=C(S1)C(=O)O.COC(=O)C=1SC(=CC1)C(CC)(CO)CC Chemical compound C(C)C(CC)(CO)C1=CC=C(S1)C(=O)O.COC(=O)C=1SC(=CC1)C(CC)(CO)CC VQKJMULJQOCYIU-UHFFFAOYSA-N 0.000 description 1
- JWLQJNXHIGKUSH-UHFFFAOYSA-N C(C)C(CO)(CC)C=1SC=CC1.C(C)C(CC)(CO)C1=CC=C(S1)C(=O)O Chemical compound C(C)C(CO)(CC)C=1SC=CC1.C(C)C(CC)(CO)C1=CC=C(S1)C(=O)O JWLQJNXHIGKUSH-UHFFFAOYSA-N 0.000 description 1
- SCIYVGKTOFNNJM-UHFFFAOYSA-N C(CCCC)(=O)C1=CC=C(C=C1)OB(O)O Chemical compound C(CCCC)(=O)C1=CC=C(C=C1)OB(O)O SCIYVGKTOFNNJM-UHFFFAOYSA-N 0.000 description 1
- HTYBLKLKNYWGOG-UHFFFAOYSA-N C1(CCCCC1)C1=CC=C(C=C1)OB(O)O Chemical compound C1(CCCCC1)C1=CC=C(C=C1)OB(O)O HTYBLKLKNYWGOG-UHFFFAOYSA-N 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- CEOZOHNUVKESEL-UHFFFAOYSA-N CC(C)(C)CCCCC(c1ccc(C(NCCC(O)=O)=O)[s]1)Sc(cc1C)cc(C)c1-c1ccc(C(C)(C)C)cc1 Chemical compound CC(C)(C)CCCCC(c1ccc(C(NCCC(O)=O)=O)[s]1)Sc(cc1C)cc(C)c1-c1ccc(C(C)(C)C)cc1 CEOZOHNUVKESEL-UHFFFAOYSA-N 0.000 description 1
- JXUMXODUYYVEFU-UHFFFAOYSA-N CC(C)(COc(cc1C)cc(C)c1-c1ccc(C(F)(F)F)cc1)c1ccc(C(NCCC(OC)=O)=O)[s]1 Chemical compound CC(C)(COc(cc1C)cc(C)c1-c1ccc(C(F)(F)F)cc1)c1ccc(C(NCCC(OC)=O)=O)[s]1 JXUMXODUYYVEFU-UHFFFAOYSA-N 0.000 description 1
- ZAELPJOICCQGLW-UHFFFAOYSA-N CC(C)CCCCC(c1ccc(C(NCCC(O)=O)=O)[s]1)Sc(cc1C)cc(C)c1-c1ccc(C(C)(C)C)cc1 Chemical compound CC(C)CCCCC(c1ccc(C(NCCC(O)=O)=O)[s]1)Sc(cc1C)cc(C)c1-c1ccc(C(C)(C)C)cc1 ZAELPJOICCQGLW-UHFFFAOYSA-N 0.000 description 1
- RQOWUYAVRZJJML-UHFFFAOYSA-N CC(C)c(cc1)ccc1-c(c(C)c1)c(C)cc1OSc1ccc(C(NCCC(O)=O)=O)[s]1 Chemical compound CC(C)c(cc1)ccc1-c(c(C)c1)c(C)cc1OSc1ccc(C(NCCC(O)=O)=O)[s]1 RQOWUYAVRZJJML-UHFFFAOYSA-N 0.000 description 1
- PESPESSHMSFBQT-UHFFFAOYSA-N CC(CO)(C)C=1SC=CC1.OCC(C)(C)C1=CC=C(S1)C(=O)O Chemical compound CC(CO)(C)C=1SC=CC1.OCC(C)(C)C1=CC=C(S1)C(=O)O PESPESSHMSFBQT-UHFFFAOYSA-N 0.000 description 1
- JUKYBIMQRSBZNJ-UHFFFAOYSA-N CC1=C(C(=CC(=C1)S)C)C1=CC=CC=C1 Chemical compound CC1=C(C(=CC(=C1)S)C)C1=CC=CC=C1 JUKYBIMQRSBZNJ-UHFFFAOYSA-N 0.000 description 1
- BGFAGLNQSLZXNN-UHFFFAOYSA-N CC=1C(=C(C(=CC1O)C)C1=CC=C(C=C1)C(F)(F)F)C Chemical compound CC=1C(=C(C(=CC1O)C)C1=CC=C(C=C1)C(F)(F)F)C BGFAGLNQSLZXNN-UHFFFAOYSA-N 0.000 description 1
- BBCDRJPSIUEJCI-UHFFFAOYSA-N CCCC(CO)c1ccc(C(OC)=O)[s]1 Chemical compound CCCC(CO)c1ccc(C(OC)=O)[s]1 BBCDRJPSIUEJCI-UHFFFAOYSA-N 0.000 description 1
- VSKHFRSNLSJBQK-UHFFFAOYSA-N CCCC(c1ccc(C(NCCC(O)=O)=O)[s]1)OC(CC1C)=CC=C1c1ccc(C(F)(F)F)cc1 Chemical compound CCCC(c1ccc(C(NCCC(O)=O)=O)[s]1)OC(CC1C)=CC=C1c1ccc(C(F)(F)F)cc1 VSKHFRSNLSJBQK-UHFFFAOYSA-N 0.000 description 1
- BVWHYCMWHYXAKQ-UHFFFAOYSA-N CCOC(c([s]c(CO)c1)c1Cl)=O Chemical compound CCOC(c([s]c(CO)c1)c1Cl)=O BVWHYCMWHYXAKQ-UHFFFAOYSA-N 0.000 description 1
- QPTPZOBMGGGEHM-UHFFFAOYSA-N CCOC(c1ccc(C(CCC2CCCCC2)OC)[s]1)=O Chemical compound CCOC(c1ccc(C(CCC2CCCCC2)OC)[s]1)=O QPTPZOBMGGGEHM-UHFFFAOYSA-N 0.000 description 1
- MKZUGLYXRVZCNZ-UHFFFAOYSA-N CCOC(c1ccc(C(Oc(cc2C)cc(C)c2I)SCCC(F)(F)F)[s]1)=O Chemical compound CCOC(c1ccc(C(Oc(cc2C)cc(C)c2I)SCCC(F)(F)F)[s]1)=O MKZUGLYXRVZCNZ-UHFFFAOYSA-N 0.000 description 1
- NKSHQSRAFBDPMT-UHFFFAOYSA-N CCc(cc1)ccc1-c(c(C)c1)c(C)cc1OC(c1ccc(C(NCCC(O)=O)=O)[s]1)S Chemical compound CCc(cc1)ccc1-c(c(C)c1)c(C)cc1OC(c1ccc(C(NCCC(O)=O)=O)[s]1)S NKSHQSRAFBDPMT-UHFFFAOYSA-N 0.000 description 1
- WZNDEZVGDUJUCZ-UHFFFAOYSA-N COC(=O)C=1SC(=CC1)C(CO)(C)C.COC(=O)C=1SC(=CC1)C(COC1=CC(=C(C(=C1)C)C1=CC=C(C=C1)C(F)(F)F)C)(C)C Chemical compound COC(=O)C=1SC(=CC1)C(CO)(C)C.COC(=O)C=1SC(=CC1)C(COC1=CC(=C(C(=C1)C)C1=CC=C(C=C1)C(F)(F)F)C)(C)C WZNDEZVGDUJUCZ-UHFFFAOYSA-N 0.000 description 1
- ICPRHCIJVGEURY-UHFFFAOYSA-N COC(C(C)(C=1SC=CC1)C)=O.C(C)C(CO)(CC)C=1SC=CC1 Chemical compound COC(C(C)(C=1SC=CC1)C)=O.C(C)C(CO)(CC)C=1SC=CC1 ICPRHCIJVGEURY-UHFFFAOYSA-N 0.000 description 1
- BSFDGMQECWWOJM-UHFFFAOYSA-N COC(C(C)(C=1SC=CC1)C)=O.CC(CO)(C)C=1SC=CC1 Chemical compound COC(C(C)(C=1SC=CC1)C)=O.CC(CO)(C)C=1SC=CC1 BSFDGMQECWWOJM-UHFFFAOYSA-N 0.000 description 1
- AQIZXIDVKWATQC-UHFFFAOYSA-N COC(c1c[s]c(C(O)S)c1)=O Chemical compound COC(c1c[s]c(C(O)S)c1)=O AQIZXIDVKWATQC-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229940121981 Carboxypeptidase inhibitor Drugs 0.000 description 1
- 101710127041 Carboxypeptidase inhibitor Proteins 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- ZTFUSLLBJVLKKC-UHFFFAOYSA-N Cc1cc(O)cc(C)c1-c1ccc(C2(F)[F][F]2)cc1 Chemical compound Cc1cc(O)cc(C)c1-c1ccc(C2(F)[F][F]2)cc1 ZTFUSLLBJVLKKC-UHFFFAOYSA-N 0.000 description 1
- IMEOLUSBFQKQIV-UHFFFAOYSA-N Cc1cc(OCC2(CC=CC2)c2ccc(C(NCCC(OC)=O)=O)[s]2)cc(C)c1-c1ccc(C(F)(F)F)cc1 Chemical compound Cc1cc(OCC2(CC=CC2)c2ccc(C(NCCC(OC)=O)=O)[s]2)cc(C)c1-c1ccc(C(F)(F)F)cc1 IMEOLUSBFQKQIV-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002911 Colestipol Polymers 0.000 description 1
- 241000270722 Crocodylidae Species 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010070901 Diabetic dyslipidaemia Diseases 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 1
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000003790 Foot Ulcer Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- GGUVRMBIEPYOKL-WMVCGJOFSA-N GW 409544 Chemical compound C([C@H](NC(/C)=C\C(=O)C=1C=CC=CC=1)C(O)=O)C(C=C1)=CC=C1OCCC(=C(O1)C)N=C1C1=CC=CC=C1 GGUVRMBIEPYOKL-WMVCGJOFSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 1
- 206010018404 Glucagonoma Diseases 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000013875 Heart injury Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000002682 Hyperkalemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229940127470 Lipase Inhibitors Drugs 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical group N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 101710140999 Metallocarboxypeptidase inhibitor Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- WMKVANSSZBSASN-UHFFFAOYSA-N OC(CCNC(c1ccc(SOc(cc2)ccc2-c2ccc(C(F)(F)F)cc2)[s]1)=O)=O Chemical compound OC(CCNC(c1ccc(SOc(cc2)ccc2-c2ccc(C(F)(F)F)cc2)[s]1)=O)=O WMKVANSSZBSASN-UHFFFAOYSA-N 0.000 description 1
- ISEJTDIAGIAUSW-UHFFFAOYSA-N OCC(C)(C)C1=CC=C(S1)C(=O)O.COC(=O)C=1SC(=CC1)C(CO)(C)C Chemical compound OCC(C)(C)C1=CC=C(S1)C(=O)O.COC(=O)C=1SC(=CC1)C(CO)(C)C ISEJTDIAGIAUSW-UHFFFAOYSA-N 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000002512 Orexin Human genes 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 1
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- MFOCDFTXLCYLKU-CMPLNLGQSA-N Phendimetrazine Chemical group O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 MFOCDFTXLCYLKU-CMPLNLGQSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 206010049416 Short-bowel syndrome Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000000019 Sterol Esterase Human genes 0.000 description 1
- 108010055297 Sterol Esterase Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000272534 Struthio camelus Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 108010071769 Thyroid Hormone Receptors beta Proteins 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- ICMGLRUYEQNHPF-UHFFFAOYSA-N Uraprene Chemical compound COC1=CC=CC=C1N1CCN(CCCNC=2N(C(=O)N(C)C(=O)C=2)C)CC1 ICMGLRUYEQNHPF-UHFFFAOYSA-N 0.000 description 1
- 102000005630 Urocortins Human genes 0.000 description 1
- 108010059705 Urocortins Proteins 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- UVSSPWOKVSKHCU-UHFFFAOYSA-N [2-(trifluoromethyl)phenoxy]boronic acid Chemical compound OB(O)OC1=CC=CC=C1C(F)(F)F UVSSPWOKVSKHCU-UHFFFAOYSA-N 0.000 description 1
- CPPSKBIDQKJJKE-UHFFFAOYSA-N [3-(trifluoromethyl)phenoxy]boronic acid Chemical compound OB(O)OC1=CC=CC(C(F)(F)F)=C1 CPPSKBIDQKJJKE-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- YTIVTFGABIZHHX-UHFFFAOYSA-L acetylenedicarboxylate(2-) Chemical compound [O-]C(=O)C#CC([O-])=O YTIVTFGABIZHHX-UHFFFAOYSA-L 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
- 229960002213 alprenolol Drugs 0.000 description 1
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000002402 anti-lipaemic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 235000021229 appetite regulation Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- FCDPQMAOJARMTG-UHFFFAOYSA-L benzylidene-[1,3-bis(2,4,6-trimethylphenyl)imidazolidin-2-ylidene]-dichlororuthenium;tricyclohexylphosphane Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1.CC1=CC(C)=CC(C)=C1N(CCN1C=2C(=CC(C)=CC=2C)C)C1=[Ru](Cl)(Cl)=CC1=CC=CC=C1 FCDPQMAOJARMTG-UHFFFAOYSA-L 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000003491 cAMP production Effects 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 102000014986 cannabinoid receptor activity proteins Human genes 0.000 description 1
- 108040006837 cannabinoid receptor activity proteins Proteins 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 1
- 229950009226 ciglitazone Drugs 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 1
- 229960002604 colestipol Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000009838 combustion analysis Methods 0.000 description 1
- 239000012612 commercial material Substances 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- QQKNSPHAFATFNQ-UHFFFAOYSA-N darglitazone Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCC(=O)C(C=C1)=CC=C1CC1SC(=O)NC1=O QQKNSPHAFATFNQ-UHFFFAOYSA-N 0.000 description 1
- 229950006689 darglitazone Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- RNOJZAYWQCKGRK-UHFFFAOYSA-N diazene hydrochloride Chemical compound Cl.N=N RNOJZAYWQCKGRK-UHFFFAOYSA-N 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 229960004890 diethylpropion Drugs 0.000 description 1
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
- FUZBPOHHSBDTJQ-CFOQQKEYSA-L disodium;5-[(2r)-2-[[(2r)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate Chemical compound [Na+].[Na+].C1([C@@H](O)CN[C@@H](CC=2C=C3OC(OC3=CC=2)(C([O-])=O)C([O-])=O)C)=CC=CC(Cl)=C1 FUZBPOHHSBDTJQ-CFOQQKEYSA-L 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960001389 doxazosin Drugs 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- 229950009714 ecopipam Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229950002375 englitazone Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- GABWWKJKXODEGI-UHFFFAOYSA-N ethyl 3-[1-[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenyl]sulfanylpropyl]thiophene-2-carboxylate Chemical compound C(C)OC(=O)C=1SC=CC1C(CC)SC1=CC(=C(C(=C1)C)C1=CC=C(C=C1)C(F)(F)F)C GABWWKJKXODEGI-UHFFFAOYSA-N 0.000 description 1
- YBSVKBPLQGTGAG-UHFFFAOYSA-N ethyl 3-[[5-[1-[4-(4-tert-butylphenyl)-3,5-dimethylphenoxy]-2-methylpropyl]thiophene-2-carbonyl]amino]-2-hydroxypropanoate Chemical compound S1C(C(=O)NCC(O)C(=O)OCC)=CC=C1C(C(C)C)OC1=CC(C)=C(C=2C=CC(=CC=2)C(C)(C)C)C(C)=C1 YBSVKBPLQGTGAG-UHFFFAOYSA-N 0.000 description 1
- BLQUEYLSBBYPKM-UHFFFAOYSA-N ethyl 3-chlorothiophene-2-carboxylate Chemical compound CCOC(=O)C=1SC=CC=1Cl BLQUEYLSBBYPKM-UHFFFAOYSA-N 0.000 description 1
- YBYVEDFQIMUYJV-UHFFFAOYSA-N ethyl 5-(1-hydroxy-2,2-dimethylpropyl)thiophene-2-carboxylate Chemical compound CCOC(=O)C1=CC=C(C(O)C(C)(C)C)S1 YBYVEDFQIMUYJV-UHFFFAOYSA-N 0.000 description 1
- YEHZXCVATFDECG-UHFFFAOYSA-N ethyl 5-(1-hydroxy-3,3-dimethylbutyl)thiophene-2-carboxylate Chemical compound CCOC(=O)C1=CC=C(C(O)CC(C)(C)C)S1 YEHZXCVATFDECG-UHFFFAOYSA-N 0.000 description 1
- IBTLASJJKFNVHN-UHFFFAOYSA-N ethyl 5-(1-hydroxy-3-methylbutyl)thiophene-2-carboxylate Chemical compound CCOC(=O)C1=CC=C(C(O)CC(C)C)S1 IBTLASJJKFNVHN-UHFFFAOYSA-N 0.000 description 1
- OQYBJPSIPCOBRM-UHFFFAOYSA-N ethyl 5-(1-hydroxybutyl)thiophene-2-carboxylate Chemical compound CCCC(O)C1=CC=C(C(=O)OCC)S1 OQYBJPSIPCOBRM-UHFFFAOYSA-N 0.000 description 1
- VDTIABHKJJZFBL-UHFFFAOYSA-N ethyl 5-(1-hydroxypentyl)thiophene-2-carboxylate Chemical compound CCCCC(O)C1=CC=C(C(=O)OCC)S1 VDTIABHKJJZFBL-UHFFFAOYSA-N 0.000 description 1
- TZPQHTQPILHDAW-UHFFFAOYSA-N ethyl 5-(2-hydroxypropan-2-yl)thiophene-2-carboxylate Chemical compound CCOC(=O)C1=CC=C(C(C)(C)O)S1 TZPQHTQPILHDAW-UHFFFAOYSA-N 0.000 description 1
- WXRUJTCVDHKLDB-UHFFFAOYSA-N ethyl 5-[1-(4-bromo-3,5-dimethylphenyl)sulfanyl-4,4,4-trifluorobutyl]thiophene-2-carboxylate Chemical compound S1C(C(=O)OCC)=CC=C1C(CCC(F)(F)F)SC1=CC(C)=C(Br)C(C)=C1 WXRUJTCVDHKLDB-UHFFFAOYSA-N 0.000 description 1
- WASMNGJOZJWCLM-UHFFFAOYSA-N ethyl 5-[1-[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenoxy]-4,4,4-trifluorobutyl]thiophene-2-carboxylate Chemical compound S1C(C(=O)OCC)=CC=C1C(CCC(F)(F)F)OC1=CC(C)=C(C=2C=CC(=CC=2)C(F)(F)F)C(C)=C1 WASMNGJOZJWCLM-UHFFFAOYSA-N 0.000 description 1
- PZAYJKJBLRWFCD-UHFFFAOYSA-N ethyl 5-[1-[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenyl]sulfanyl-2-methylpropyl]thiophene-2-carboxylate Chemical compound S1C(C(=O)OCC)=CC=C1C(C(C)C)SC1=CC(C)=C(C=2C=CC(=CC=2)C(F)(F)F)C(C)=C1 PZAYJKJBLRWFCD-UHFFFAOYSA-N 0.000 description 1
- WEKMNICKDQGVAQ-UHFFFAOYSA-N ethyl 5-[1-[4-(4-tert-butylphenyl)-3,5-dimethylphenoxy]-4,4,4-trifluorobutyl]thiophene-2-carboxylate Chemical compound S1C(C(=O)OCC)=CC=C1C(CCC(F)(F)F)OC1=CC(C)=C(C=2C=CC(=CC=2)C(C)(C)C)C(C)=C1 WEKMNICKDQGVAQ-UHFFFAOYSA-N 0.000 description 1
- YBJWUWZEBPCWOG-UHFFFAOYSA-N ethyl 5-[4,4,4-trifluoro-1-(4-iodo-3,5-dimethylphenoxy)butyl]thiophene-2-carboxylate Chemical compound S1C(C(=O)OCC)=CC=C1C(CCC(F)(F)F)OC1=CC(C)=C(I)C(C)=C1 YBJWUWZEBPCWOG-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- ZZCHHVUQYRMYLW-HKBQPEDESA-N farglitazar Chemical compound N([C@@H](CC1=CC=C(C=C1)OCCC=1N=C(OC=1C)C=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 ZZCHHVUQYRMYLW-HKBQPEDESA-N 0.000 description 1
- 238000010265 fast atom bombardment Methods 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 229960001582 fenfluramine Drugs 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 238000000434 field desorption mass spectrometry Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000004116 glycogenolysis Effects 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- KKLGDUSGQMHBPB-UHFFFAOYSA-N hex-2-ynedioic acid Chemical compound OC(=O)CCC#CC(O)=O KKLGDUSGQMHBPB-UHFFFAOYSA-N 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- BICAGYDGRXJYGD-UHFFFAOYSA-N hydrobromide;hydrochloride Chemical compound Cl.Br BICAGYDGRXJYGD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- SQKXYSGRELMAAU-UHFFFAOYSA-N imidafenacin Chemical compound CC1=NC=CN1CCC(C(N)=O)(C=1C=CC=CC=1)C1=CC=CC=C1 SQKXYSGRELMAAU-UHFFFAOYSA-N 0.000 description 1
- 229950005396 imidafenacin Drugs 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical compound [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 description 1
- 238000001038 ionspray mass spectrometry Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- JNODQFNWMXFMEV-UHFFFAOYSA-N latrepirdine Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1 JNODQFNWMXFMEV-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000003615 lipoprotein lipase activator Substances 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 238000006138 lithiation reaction Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- CQRPUKWAZPZXTO-UHFFFAOYSA-M magnesium;2-methylpropane;chloride Chemical compound [Mg+2].[Cl-].C[C-](C)C CQRPUKWAZPZXTO-UHFFFAOYSA-M 0.000 description 1
- GFTXWCQFWLOXAT-UHFFFAOYSA-M magnesium;cyclohexane;bromide Chemical compound [Mg+2].[Br-].C1CC[CH-]CC1 GFTXWCQFWLOXAT-UHFFFAOYSA-M 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- XWCQLLDGXBLGMD-UHFFFAOYSA-M magnesium;pentane;bromide Chemical compound [Mg+2].[Br-].CCCC[CH2-] XWCQLLDGXBLGMD-UHFFFAOYSA-M 0.000 description 1
- JFWWQYKSQVMLQU-UHFFFAOYSA-M magnesium;pentane;chloride Chemical compound [Mg+2].[Cl-].CCCC[CH2-] JFWWQYKSQVMLQU-UHFFFAOYSA-M 0.000 description 1
- UGVPKMAWLOMPRS-UHFFFAOYSA-M magnesium;propane;bromide Chemical compound [Mg+2].[Br-].CC[CH2-] UGVPKMAWLOMPRS-UHFFFAOYSA-M 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960000299 mazindol Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- LPEKGGXMPWTOCB-UHFFFAOYSA-N methyl 2-hydroxypropionate Chemical compound COC(=O)C(C)O LPEKGGXMPWTOCB-UHFFFAOYSA-N 0.000 description 1
- QHTYENTWFSNKTR-UHFFFAOYSA-N methyl 3-[[4-chloro-5-[1-[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenoxy]propyl]thiophene-2-carbonyl]amino]propanoate Chemical compound S1C(C(=O)NCCC(=O)OC)=CC(Cl)=C1C(CC)OC(C=C1C)=CC(C)=C1C1=CC=C(C(F)(F)F)C=C1 QHTYENTWFSNKTR-UHFFFAOYSA-N 0.000 description 1
- JXJNEJNVSIEISC-UHFFFAOYSA-N methyl 3-[[5-[1-(3,5-dimethylphenoxy)-3-methylbutyl]thiophene-2-carbonyl]amino]propanoate Chemical compound S1C(C(=O)NCCC(=O)OC)=CC=C1C(CC(C)C)OC1=CC(C)=CC(C)=C1 JXJNEJNVSIEISC-UHFFFAOYSA-N 0.000 description 1
- QABYFDWXFQXSBD-UHFFFAOYSA-N methyl 3-[[5-[1-(4-bromo-3,5-dimethylphenoxy)-3-methylbutyl]thiophene-2-carbonyl]amino]propanoate Chemical compound S1C(C(=O)NCCC(=O)OC)=CC=C1C(CC(C)C)OC1=CC(C)=C(Br)C(C)=C1 QABYFDWXFQXSBD-UHFFFAOYSA-N 0.000 description 1
- CWPXNKNTLYOWKY-UHFFFAOYSA-N methyl 3-[[5-[1-[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenoxy]butan-2-yl]thiophene-2-carbonyl]amino]propanoate Chemical compound C=1C=C(C(=O)NCCC(=O)OC)SC=1C(CC)COC(C=C1C)=CC(C)=C1C1=CC=C(C(F)(F)F)C=C1 CWPXNKNTLYOWKY-UHFFFAOYSA-N 0.000 description 1
- ZSZHYYUFNLWXCL-UHFFFAOYSA-N methyl 3-[[5-[1-[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenoxy]ethyl]thiophene-2-carbonyl]amino]propanoate Chemical compound S1C(C(=O)NCCC(=O)OC)=CC=C1C(C)OC1=CC(C)=C(C=2C=CC(=CC=2)C(F)(F)F)C(C)=C1 ZSZHYYUFNLWXCL-UHFFFAOYSA-N 0.000 description 1
- AZGSSRSHNZGPSF-UHFFFAOYSA-N methyl 3-[[5-[1-[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenyl]sulfanyl-2-methylpropyl]thiophene-2-carbonyl]amino]propanoate Chemical compound S1C(C(=O)NCCC(=O)OC)=CC=C1C(C(C)C)SC1=CC(C)=C(C=2C=CC(=CC=2)C(F)(F)F)C(C)=C1 AZGSSRSHNZGPSF-UHFFFAOYSA-N 0.000 description 1
- FGFQWUPCNOHEPW-UHFFFAOYSA-N methyl 3-[[5-[1-[4-(4-tert-butylphenyl)-3,5-dimethylphenoxy]-4,4,4-trifluorobutyl]thiophene-2-carbonyl]amino]propanoate Chemical compound S1C(C(=O)NCCC(=O)OC)=CC=C1C(CCC(F)(F)F)OC1=CC(C)=C(C=2C=CC(=CC=2)C(C)(C)C)C(C)=C1 FGFQWUPCNOHEPW-UHFFFAOYSA-N 0.000 description 1
- PGXGSVORKGGXFB-UHFFFAOYSA-N methyl 3-[[5-[1-[4-(4-tert-butylphenyl)-3,5-dimethylphenoxy]butan-2-yl]thiophene-2-carbonyl]amino]propanoate Chemical compound C=1C=C(C(=O)NCCC(=O)OC)SC=1C(CC)COC(C=C1C)=CC(C)=C1C1=CC=C(C(C)(C)C)C=C1 PGXGSVORKGGXFB-UHFFFAOYSA-N 0.000 description 1
- YQXCQURLXWFNTO-UHFFFAOYSA-N methyl 3-[[5-[1-[4-(4-tert-butylphenyl)-3,5-dimethylphenyl]sulfanylethyl]thiophene-2-carbonyl]amino]propanoate Chemical compound S1C(C(=O)NCCC(=O)OC)=CC=C1C(C)SC1=CC(C)=C(C=2C=CC(=CC=2)C(C)(C)C)C(C)=C1 YQXCQURLXWFNTO-UHFFFAOYSA-N 0.000 description 1
- XEHZRUUBZPVDPI-UHFFFAOYSA-N methyl 3-[[5-[1-[[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]phenoxy]methyl]cyclopentyl]thiophene-2-carbonyl]amino]propanoate Chemical compound S1C(C(=O)NCCC(=O)OC)=CC=C1C1(COC=2C=C(C)C(=C(C)C=2)C=2C=CC(=CC=2)C(F)(F)F)CCCC1 XEHZRUUBZPVDPI-UHFFFAOYSA-N 0.000 description 1
- CHXRBSJRNVLZFT-UHFFFAOYSA-N methyl 3-[[5-[3-methyl-1-[4-[4-(trifluoromethyl)phenyl]phenoxy]butyl]thiophene-2-carbonyl]amino]propanoate Chemical compound S1C(C(=O)NCCC(=O)OC)=CC=C1C(CC(C)C)OC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 CHXRBSJRNVLZFT-UHFFFAOYSA-N 0.000 description 1
- ACNSROARLRIDDM-UHFFFAOYSA-N methyl 5-(1-hydroxy-2-methylpropan-2-yl)thiophene-2-carboxylate Chemical compound COC(=O)C1=CC=C(C(C)(C)CO)S1 ACNSROARLRIDDM-UHFFFAOYSA-N 0.000 description 1
- GMUYDUABZORLID-UHFFFAOYSA-N methyl 5-[3-(hydroxymethyl)pentan-3-yl]thiophene-2-carboxylate Chemical compound CCC(CC)(CO)C1=CC=C(C(=O)OC)S1 GMUYDUABZORLID-UHFFFAOYSA-N 0.000 description 1
- GNXNZRYWBFMVHK-UHFFFAOYSA-N methyl 5-formylthiophene-3-carboxylate Chemical compound COC(=O)C1=CSC(C=O)=C1 GNXNZRYWBFMVHK-UHFFFAOYSA-N 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 229960003365 mitiglinide Drugs 0.000 description 1
- WPGGHFDDFPHPOB-BBWFWOEESA-N mitiglinide Chemical compound C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)O)C1=CC=CC=C1 WPGGHFDDFPHPOB-BBWFWOEESA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- PHWISQNXPLXQRU-UHFFFAOYSA-N n,n-dimethylcarbamothioyl chloride Chemical compound CN(C)C(Cl)=S PHWISQNXPLXQRU-UHFFFAOYSA-N 0.000 description 1
- DNEJTAGALVCNCG-UHFFFAOYSA-N n-(dimethylamino)carbamothioyl chloride Chemical compound CN(C)NC(Cl)=S DNEJTAGALVCNCG-UHFFFAOYSA-N 0.000 description 1
- BFYLULHOYZNWPC-UHFFFAOYSA-N n-[[4,5-dimethyl-1-[(2-methylphenyl)methyl]imidazol-2-yl]methyl]-2,4-dimethoxy-n-(3-methylbutyl)benzamide Chemical compound COC1=CC(OC)=CC=C1C(=O)N(CCC(C)C)CC1=NC(C)=C(C)N1CC1=CC=CC=C1C BFYLULHOYZNWPC-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- SHHNNFDRANBHNT-UHFFFAOYSA-N o-(4-bromo-3,5-dimethylphenyl) n,n-dimethylcarbamothioate Chemical compound CN(C)C(=S)OC1=CC(C)=C(Br)C(C)=C1 SHHNNFDRANBHNT-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 239000003401 opiate antagonist Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 108060005714 orexin Proteins 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical group CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- YDCVQGAUCOROHB-UHFFFAOYSA-N oxadiazolidine-4,5-dione Chemical class O=C1NNOC1=O YDCVQGAUCOROHB-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- 238000010651 palladium-catalyzed cross coupling reaction Methods 0.000 description 1
- 210000002571 pancreatic alpha cell Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
- 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229960000436 phendimetrazine Drugs 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- JPHSWUBDHJSNLZ-UHFFFAOYSA-N phenyl-[2-(2-phenylphosphanylphenoxy)phenyl]phosphane Chemical compound C=1C=CC=C(PC=2C=CC=CC=2)C=1OC1=CC=CC=C1PC1=CC=CC=C1 JPHSWUBDHJSNLZ-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000018656 positive regulation of gluconeogenesis Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000003450 potassium channel blocker Substances 0.000 description 1
- 229940125422 potassium channel blocker Drugs 0.000 description 1
- 239000004036 potassium channel stimulating agent Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- XMSXOLDPMGMWTH-UHFFFAOYSA-N rivoglitazone Chemical compound CN1C2=CC(OC)=CC=C2N=C1COC(C=C1)=CC=C1CC1SC(=O)NC1=O XMSXOLDPMGMWTH-UHFFFAOYSA-N 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- HKINVPMYAKRHLN-UHFFFAOYSA-N s-[4-(4-tert-butylphenyl)-3,5-dimethylphenyl] n,n-dimethylcarbamothioate Chemical compound CC1=CC(SC(=O)N(C)C)=CC(C)=C1C1=CC=C(C(C)(C)C)C=C1 HKINVPMYAKRHLN-UHFFFAOYSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 230000002295 serotoninergic effect Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 159000000000 sodium salts Chemical group 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960001693 terazosin Drugs 0.000 description 1
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- OHOVBSAWJQSRDD-UHFFFAOYSA-N thiophen-2-yloxyboronic acid Chemical compound OB(O)OC1=CC=CS1 OHOVBSAWJQSRDD-UHFFFAOYSA-N 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 229960001130 urapidil Drugs 0.000 description 1
- 239000000777 urocortin Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65249205P | 2005-02-11 | 2005-02-11 | |
| US60/652,492 | 2005-02-11 | ||
| PCT/US2006/004461 WO2006086488A2 (en) | 2005-02-11 | 2006-02-09 | Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008530102A JP2008530102A (ja) | 2008-08-07 |
| JP2008530102A5 JP2008530102A5 (enExample) | 2009-03-26 |
| JP4988604B2 true JP4988604B2 (ja) | 2012-08-01 |
Family
ID=36694345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007555195A Expired - Fee Related JP4988604B2 (ja) | 2005-02-11 | 2006-02-09 | グルカゴン受容体アンタゴニストとしての置換チオフェン誘導体、その調製及び治療への使用 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8084489B2 (enExample) |
| EP (1) | EP1856090B1 (enExample) |
| JP (1) | JP4988604B2 (enExample) |
| KR (1) | KR20070104409A (enExample) |
| CN (1) | CN101115735B (enExample) |
| AT (1) | ATE445609T1 (enExample) |
| AU (1) | AU2006213894B2 (enExample) |
| BR (1) | BRPI0607015A2 (enExample) |
| CA (1) | CA2597073C (enExample) |
| CR (1) | CR9304A (enExample) |
| CY (1) | CY1109624T1 (enExample) |
| DE (1) | DE602006009773D1 (enExample) |
| DK (1) | DK1856090T3 (enExample) |
| EA (1) | EA200701705A1 (enExample) |
| ES (1) | ES2332470T3 (enExample) |
| IL (1) | IL184932A0 (enExample) |
| MA (1) | MA29432B1 (enExample) |
| MX (1) | MX2007009661A (enExample) |
| NO (1) | NO20074567L (enExample) |
| PL (1) | PL1856090T3 (enExample) |
| PT (1) | PT1856090E (enExample) |
| SI (1) | SI1856090T1 (enExample) |
| TN (1) | TNSN07313A1 (enExample) |
| WO (1) | WO2006086488A2 (enExample) |
| ZA (1) | ZA200706354B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1758853T1 (sl) * | 2004-06-14 | 2010-05-31 | Lilly Co Eli | Antagonisti glukagonskega receptorja priprava inuporaba v terapiji |
| ES2494294T3 (es) | 2007-02-09 | 2014-09-15 | Metabasis Therapeutics, Inc. | Antagonistas del receptor de glucagón |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| ES2714207T3 (es) | 2008-08-13 | 2019-05-27 | Metabasis Therapeutics Inc | Antagonistas de glucagón |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| BR112013016033A2 (pt) | 2010-12-23 | 2018-06-05 | Pfizer | moduladores do receptor de glucagon |
| ES2597972T3 (es) | 2011-02-08 | 2017-01-24 | Pfizer Inc | Modulador del receptor de glucagón |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8927577B2 (en) | 2011-07-22 | 2015-01-06 | Pfizer Inc. | Quinolinyl glucagon receptor modulators |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| TW201427658A (zh) | 2012-12-10 | 2014-07-16 | Merck Sharp & Dohme | 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法 |
| WO2015066252A1 (en) | 2013-11-04 | 2015-05-07 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions thereof, and methods of use |
| JP2017519000A (ja) | 2014-06-12 | 2017-07-13 | リガンド・ファーマシューティカルズ・インコーポレイテッド | グルカゴンアンタゴニスト |
| EP3350200A4 (en) | 2015-09-18 | 2019-03-27 | Wake Forest University Health Services | ANGIOTENSIN (1 7) ANALOGUE AND ASSOCIATED PROCEDURES |
| EP3821917A1 (en) | 2015-10-05 | 2021-05-19 | Hettwer Holding ApS | Compositions and methods for treatment of bone defects |
| CA2914601A1 (en) * | 2015-12-11 | 2017-06-11 | Wake Forest University Health Sciences | Angiotensin-(1-7) analogs and methods relating thereto |
| SG11201901355SA (en) | 2016-08-30 | 2019-03-28 | Regeneron Pharma | Methods of treating severe insulin resistance by interfering with glucagon receptor signaling |
| EP3529278A1 (en) | 2016-10-20 | 2019-08-28 | Regeneron Pharmaceuticals, Inc. | Methods of lowering blood glucose levels |
| US12139546B2 (en) | 2017-08-22 | 2024-11-12 | Regeneron Pharmaceuticals, Inc. | Methods of treating urea cycle disorders by interfering with glucagon receptor signaling |
| TW202003453A (zh) | 2018-02-13 | 2020-01-16 | 美商利根德製藥公司 | 升糖素受體拮抗劑 |
| CN118496197A (zh) | 2019-12-20 | 2024-08-16 | 拜耳公司 | 取代的噻吩甲酰胺、噻吩甲酸及其衍生物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002365622A1 (en) * | 2001-12-03 | 2003-06-17 | Novo Nordisk A/S | Novel glucagon antagonists |
| AU2003233780A1 (en) * | 2002-06-27 | 2004-01-19 | Novo Nordisk A/S | Novel glucagon antagonists/inverse agonists |
| WO2005118542A1 (en) * | 2004-05-28 | 2005-12-15 | Eli Lilly And Company | Glucagon receptor antagonists, preparation and therapeutic uses |
| SI1758853T1 (sl) * | 2004-06-14 | 2010-05-31 | Lilly Co Eli | Antagonisti glukagonskega receptorja priprava inuporaba v terapiji |
-
2006
- 2006-02-09 MX MX2007009661A patent/MX2007009661A/es active IP Right Grant
- 2006-02-09 DE DE602006009773T patent/DE602006009773D1/de active Active
- 2006-02-09 SI SI200630534T patent/SI1856090T1/sl unknown
- 2006-02-09 AU AU2006213894A patent/AU2006213894B2/en not_active Ceased
- 2006-02-09 EP EP06720513A patent/EP1856090B1/en active Active
- 2006-02-09 AT AT06720513T patent/ATE445609T1/de active
- 2006-02-09 CA CA2597073A patent/CA2597073C/en not_active Expired - Fee Related
- 2006-02-09 PL PL06720513T patent/PL1856090T3/pl unknown
- 2006-02-09 ES ES06720513T patent/ES2332470T3/es active Active
- 2006-02-09 EA EA200701705A patent/EA200701705A1/ru unknown
- 2006-02-09 CN CN2006800046189A patent/CN101115735B/zh not_active Expired - Fee Related
- 2006-02-09 PT PT06720513T patent/PT1856090E/pt unknown
- 2006-02-09 BR BRPI0607015-9A patent/BRPI0607015A2/pt not_active IP Right Cessation
- 2006-02-09 DK DK06720513T patent/DK1856090T3/da active
- 2006-02-09 JP JP2007555195A patent/JP4988604B2/ja not_active Expired - Fee Related
- 2006-02-09 US US11/815,987 patent/US8084489B2/en not_active Expired - Fee Related
- 2006-02-09 WO PCT/US2006/004461 patent/WO2006086488A2/en not_active Ceased
- 2006-02-09 KR KR1020077018437A patent/KR20070104409A/ko not_active Ceased
-
2007
- 2007-07-30 IL IL184932A patent/IL184932A0/en unknown
- 2007-07-31 ZA ZA200706354A patent/ZA200706354B/xx unknown
- 2007-08-10 CR CR9304A patent/CR9304A/es not_active Application Discontinuation
- 2007-08-10 TN TNP2007000313A patent/TNSN07313A1/en unknown
- 2007-09-10 NO NO20074567A patent/NO20074567L/no not_active Application Discontinuation
- 2007-09-11 MA MA30221A patent/MA29432B1/fr unknown
-
2009
- 2009-11-12 CY CY20091101192T patent/CY1109624T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006086488A3 (en) | 2006-12-14 |
| EP1856090B1 (en) | 2009-10-14 |
| DK1856090T3 (da) | 2009-11-30 |
| JP2008530102A (ja) | 2008-08-07 |
| MA29432B1 (fr) | 2008-05-02 |
| EA200701705A1 (ru) | 2008-02-28 |
| NO20074567L (no) | 2007-11-08 |
| BRPI0607015A2 (pt) | 2009-12-01 |
| CN101115735B (zh) | 2013-01-09 |
| ATE445609T1 (de) | 2009-10-15 |
| MX2007009661A (es) | 2007-09-25 |
| WO2006086488A2 (en) | 2006-08-17 |
| KR20070104409A (ko) | 2007-10-25 |
| IL184932A0 (en) | 2007-12-03 |
| PL1856090T3 (pl) | 2010-02-26 |
| CR9304A (es) | 2008-03-31 |
| TNSN07313A1 (en) | 2008-12-31 |
| CY1109624T1 (el) | 2014-08-13 |
| CA2597073A1 (en) | 2006-08-17 |
| ZA200706354B (en) | 2008-11-26 |
| US20100137417A1 (en) | 2010-06-03 |
| CA2597073C (en) | 2014-11-25 |
| SI1856090T1 (sl) | 2010-02-26 |
| PT1856090E (pt) | 2009-11-18 |
| CN101115735A (zh) | 2008-01-30 |
| EP1856090A2 (en) | 2007-11-21 |
| US8084489B2 (en) | 2011-12-27 |
| AU2006213894A1 (en) | 2006-08-17 |
| ES2332470T3 (es) | 2010-02-05 |
| DE602006009773D1 (de) | 2009-11-26 |
| AU2006213894B2 (en) | 2011-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4988604B2 (ja) | グルカゴン受容体アンタゴニストとしての置換チオフェン誘導体、その調製及び治療への使用 | |
| JP5107253B2 (ja) | グルカゴン受容体アンタゴニスト、並びにその調製及び治療への使用 | |
| JP5140599B2 (ja) | グルカゴン受容体アンタゴニスト、並びにその調製及び治療への使用 | |
| JP5198280B2 (ja) | グルカゴン受容体アンタゴニスト、並びにその調製及び治療への使用 | |
| JP5000492B2 (ja) | グルカゴン受容体拮抗物質及びその調製並びに治療的使用 | |
| JP5230436B2 (ja) | グルカゴン受容体アンタゴニスト、製造及び治療的使用 | |
| EP1758859B1 (en) | Glucagon receptor antagonists, preparation and therapeutic uses | |
| JP5100657B2 (ja) | グルカゴン受容体アンタゴニストおよびその製造及び治療用途 | |
| MX2008006699A (en) | Glucagon receptor antagonists, preparation and therapeutic uses | |
| EP1951659A2 (en) | Glucagon receptor antagonists, preparation and therapeutic uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090205 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090205 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20111122 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111206 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120305 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120403 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120426 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150511 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |